Chief Minister's Comprehensive Health Insurance Scheme

Package Rates

BARIATRIC SURGERY	CARDIOLOGY	CARDIOTHORACIC SURGERIES	DERMATOLOGY	Diagnostic center	E N T	Emergency Room Packages (Care requiring less than 12 hrs stay)
ENDOCRINE SURGERY	ENDOCRINOLOGY	FOLLOW UP PROCEDURE	GASTROENTEROLOGY	GENERAL MEDICINE	GENERAL SURGERY	GENITOURINARY SURGERY
GYNAECOLOGY OBSTETRIC SURGERY	HEMATOLOGY	HEPATOLOGY	INFECTIOUS DISEASES - GENERAL MEDICINE	INTERVENTIONAL CARDIOLOGY	INTERVENTIONAL RADIOLOGY	MEDICAL ONCOLOGY
NEONATOLOGY	NEPHROLOGY	NEUROLOGY	NEUROSURGERY	OFMS	OPHTHALMOLOGY SURGERIES	ORTHOPEDIC TRAUMA
PAEDIATRIC INTENSIVE CARE	PAEDIATRIC SURGERIES	PAEDIATRICS	PLASTIC SURGERY	PMR	PSYCHIATRY	PULMONLOGY
RADIATION ONCOLOGY	RHEUMATOLOGY	SPINE	STEMI	SURGICAL GASTRO ENTEROLOGY	SURGICAL ONCOLOGY	THORACIC MEDICINE
VASCULAR SURGERIES

Package Name	Category	A1	A2	A3	A4	A5	A6	S1	S2
CM0100 : BREAST CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0100-a : BREAST CANCER - combined regimen AC & T	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0100-a-I : BREAST CANCER - Dose Dense AC (Adriamycin/Cyclophosphamide) ; (Day 1: Doxorubicin 60mg/m2 IV, Cyclophosphamide 600mg/m2 IV) ; Repeat cycle - every 14 days for 4 cycles; Followed by Paclitaxel for 4 cycles	MEDICAL ONCOLOGY	3000	3000	3000	3000	3000	3000	3000	3000
CM0100-a-II : BREAST CANCER - Paclitaxel (Preceeded by Dose Dense AC - 4 cycles) ; (Day 1: Paclitaxel 175mg/m2) Repeat cycle - every 14 days for 4 cycles	MEDICAL ONCOLOGY	7000	7000	7000	7000	7000	7000	7000	7000
CM0100-b : BREAST CANCER - TC (Doectaxel & Cyclophosphamide) ; Day 1: Docetaxel 75mg/m2 IV, Cyclophosphamide 600mg/m2 IV ; Repeat cycle - every 21 days for 4 cycles	MEDICAL ONCOLOGY	6000	6000	6000	6000	6000	6000	6000	6000
CM0100-c : BREAST CANCER - CMF (Cyclophosphamide/Methotrexate/Fluorouracil) - (includes day 1 & day 8) ; Days 1-14: Cyclophosphamide 100mg/m2 orally ; Days 1 and 8: Methotrexate 40mg/m2 IV ; Days 1 and 8: 5-fluorouracil 600mg/m2 IV. ; Repeat cycle - every 28 days for 6 cycles	MEDICAL ONCOLOGY	2700	2700	2700	2700	2700	2700	2700	2700
CM0100-d : BREAST CANCER - EC (Epirubicin/Cyclophosphamide) ; Day 1: Epirubicin 100mg/m2 IV ; Day 1: Cyclophosphamide 830mg/m2 IV. ; Repeat cycle - every 21 days for 8 cycles	MEDICAL ONCOLOGY	5100	5100	5100	5100	5100	5100	5100	5100
CM0100-e : BREAST CANCER - FEC + T	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0100-e-I : BREAST CANCER - FEC/CEF followed by T (Fluorouracil/Epirubicin/Cyclophosphamide) - followed by Docetaxel or followed by weekly Paclitaxel) ; Day 1: 5-fluorouracil 500mg/m2 IV ; Day 1: Epirubicin 100mg/m2 IV ; Day 1: Cyclophosphamide 500mg/m2 IV. ; Repeat cycle every 21 days for 3 cycles	MEDICAL ONCOLOGY	5100	5100	5100	5100	5100	5100	5100	5100
CM0100-e-II : BREAST CANCER - Docetaxel - (Preceeded by FEC/CEF ) ; Day 1: Docetaxel 100mg/m2 IV. ; Repeat cycle - every 21 days for 3 cycles	MEDICAL ONCOLOGY	5500	5500	5500	5500	5500	5500	5500	5500
CM0100-e-III : BREAST CANCER - Paclitaxel - weekly - (Preceeded by FEC/CEF ) ; Paclitaxel 100mg/m2 IV ; Repeat cycle - once weekly for 8 weeks	MEDICAL ONCOLOGY	3500	3500	3500	3500	3500	3500	3500	3500
CM0100-f : BREAST CANCER - FAC + T	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0100-f-I : BREAST CANCER - FAC followed by T (Fluorouracil/Adriamycin/Cyclophosphamide) - followed by weekly Paclitaxel ; 5-fluorouracil 500mg/m2 IV Days 1 and 8 OR 1 and 4: ; Day 1: Doxorubicin 50mg/m2 IV ; Day 1: Cyclophosphamide 500mg/m2 IV. ; Repeat cycle - every 21 days for 6 cycles	MEDICAL ONCOLOGY	3200	3200	3200	3200	3200	3200	3200	3200
CM0100-f-II : BREAST CANCER - Paclitaxel - weekly - Preceeded by FAC ; Paclitaxel 80mg/m2 IV ; Repeat Cycle weekly for 12 weeks.	MEDICAL ONCOLOGY	3500	3500	3500	3500	3500	3500	3500	3500
CM0100-g : BREAST CANCER - TAC (Docetaxel/Adriamycin/Cyclophosphamide) ; Day 1: Doxorubicin 60mg/m2 IV ; Day 1: Cyclophosphamide 600mg/m2 IV. ; Day 1: Docetaxel 100mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles,	MEDICAL ONCOLOGY	5600	5600	5600	5600	5600	5600	5600	5600
CM0100-h : BREAST CANCER - AC followed by T + Trastuzumab	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0100-h-I : BREAST CANCER - AC - followed by Paclitaxel + Trastuzumab +/- Pertuzumab ; Day 1: Doxorubicin 60mg/m2 IV ; Day 1: Cyclophosphamide 600mg/m2 IV. ; Repeat cycle - every 21 days for 4 cycle	MEDICAL ONCOLOGY	3000	3000	3000	3000	3000	3000	3000	3000
CM0100-h-II : BREAST CANCER - Paclitaxel (Preceeded by AC) ; (To be choosen along with Trastuzumab package - CM0100-h-III or CM0100-h-IV or CM0100-h-V) ; Paclitaxel 80mg/m2 IV. ; Repeat Cycle weekly for 12 weeks.	MEDICAL ONCOLOGY	3500	3500	3500	3500	3500	3500	3500	3500
CM0100-h-III : BREAST CANCER - Trastuzumab (6mg) ; (to be choosen along with Paclitaxel package CM0100-h-II) ; Day 1: Trastuzumab 6mg/kg IV ; Repeat cycle every 21 days to complete 1 year. ; (to be approved with Paclitaxel Cycle 1, 4, 7, 10 and standalone for the upto 1 year every 21 days)	MEDICAL ONCOLOGY	30500	30500	30500	30500	30500	30500	30500	30500
CM0100-h-IV : BREAST CANCER - Trastuzumab 4mg (Followed by Trastuzumab 2mg subsequent weeks) ; (to be choosen along with Paclitaxel package CM0100-h-II) ; Day 1: Trastuzumab 4mg/kg IV with first dose of paclitaxel. ; (First dose - only to be approved with Paclitaxel Cycle 1. Subsequent cycles - 2mg package only)	MEDICAL ONCOLOGY	30500	30500	30500	30500	30500	30500	30500	30500
CM0100-h-V : BREAST CANCER - Trastuzumab 2mg (Subsequent doses) ; (to be choosen along with Paclitaxel package CM0100-h-II) ; Day 1: Trastuzumab 2mg/kg IV weekly Till one year from Day 1 of AC. ; (to be approved with Paclitaxel Cycles 2 - 12 and standalone for the upto 1 year every week)	MEDICAL ONCOLOGY	11500	11500	11500	11500	11500	11500	11500	11500
CM0100-i : BREAST CANCER - TCH	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0100-i-I : BREAST CANCER - TC (Docetaxel/Carboplatin) ; (To be choosen along with Trastuzumab package - CM0100-i-II or CM0100-i-III or CM0100-i-IV) ; Day 1: Docetaxel 75mg/m2 IV; Carboplatin AUC 6mg per min/mL IV. ; every 21 days for 6 cycles	MEDICAL ONCOLOGY	7100	7100	7100	7100	7100	7100	7100	7100
CM0100-i-II : BREAST CANCER - Trastuzumab (6mg) ; (to be choosen along with TC package CM0100-i-I) ; Trastuzumab 6mg/kg IV ; Repeat cycle every 21 days to complete 1 year. ; (to be approved with TC Cycle 1 to 6 and standalone for the upto 1 year every 21 days (or) after completion of weekly trastuzumab for 18 weeks as standalone for the upto 1 year every 21 days)	MEDICAL ONCOLOGY	30500	30500	30500	30500	30500	30500	30500	30500
CM0100-i-III : BREAST CANCER - Trastuzumab 4mg (First dose - only) - followed by 2mg ; (to be choosen along with TC package CM0100-i-I) ; Day 1: Trastuzumab 4mg/kg IV ; (First dose - only to be approved with TC Cycle 1. Subsequent cycles - 2mg package only)	MEDICAL ONCOLOGY	30500	30500	30500	30500	30500	30500	30500	30500
CM0100-i-IV : BREAST CANCER - Trastuzumab 2mg (Subsequent doses - Weekly) ; Trastuzumab 2mg/kg IV ; (to be approved weekly for 17 weeeks may overlap with TC Cycles 2 - 6. To be followed by Trastuzumab (6mg) package upto 1 year	MEDICAL ONCOLOGY	11500	11500	11500	11500	11500	11500	11500	11500
CM0100-j : BREAST CANCER - AC followed by Docetaxel + Trastuzumab	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0100-j-I : BREAST CANCER - AC - followed by Docetaxel + Trastuzumab ; Day 1: Doxorubicin 60mg/m2 IV; Day 1: Cyclophosphamide 600mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles,	MEDICAL ONCOLOGY	3000	3000	3000	3000	3000	3000	3000	3000
CM0100-j-II : BREAST CANCER - Docetaxel (preceeded by AC) + Trastuzumab ; (To be choosen along with Trastuzumab package - CM0100-j-III or CM0100-j-IV or CM0100-j-V) ; Day 1: Docetaxel 100mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles	MEDICAL ONCOLOGY	5400	5400	5400	5400	5400	5400	5400	5400
CM0100-j-III : BREAST CANCER - Trastuzumab (6mg) ; (to be choosen along with Docetaxel package CM0100-j-II) ; Day 1: Trastuzumab 6mg/kg IV ; Repeat every 21 days till 1 year ; (to be approved with Docetaxel Cycle 1 to 4 and standalone for the upto 1 year every 21 days (or) or from 13 th week after completion of 12 weeks of weekly Trastuzumab - upto 1 year every 21 days)	MEDICAL ONCOLOGY	30500	30500	30500	30500	30500	30500	30500	30500
CM0100-j-IV : BREAST CANCER - Trastuzumab 4mg (First dose - only) - followed by 2mg ; (to be choosen along with Docetaxel package CM0100-j-II) ; Trastuzumab 4mg/kg IV ; (First dose - only to be approved with Docetaxel Cycle 1. Subsequent cycles - 2mg package only)	MEDICAL ONCOLOGY	30500	30500	30500	30500	30500	30500	30500	30500
CM0100-j-V : BREAST CANCER - Trastuzumab 2mg (Subsequent doses) ; Trastuzumab 2mg/kg IV ; (to be approved weekly for 11 weeeks may overlap with Docetaxel Cycles 2 - 4. To be followed by Trastuzumab (6mg) package upto 1 year)	MEDICAL ONCOLOGY	11500	11500	11500	11500	11500	11500	11500	11500
CM0100-k : BREAST CANCER - Docetaxel + Cyclophosphamide + Trastuzumab	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0100-k-I : BREAST CANCER - Docetaxel + Cyclophosphamide - with Trastuzumab ; (To be choosen along with Trastuzumab package - CM0100-k-II or CM0100-k-III or CM0100-k-IV) ; Day 1: Docetaxel 75mg/m2 IV; Cyclophosphamide 600mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles,	MEDICAL ONCOLOGY	5000	5000	5000	5000	5000	5000	5000	5000
CM0100-k-II : BREAST CANCER - Trastuzumab (6mg) ; (to be choosen along with Docetaxel + Cyclophosphamide package CM0100-k-I) ; Day 1: Trastuzumab 6mg/kg IV ; (to be approved with Docetaxel + Cyclophosphamide Cycle 1 to 4 and standalone for the upto 1 year every 21 days (or) after completion of weekly trastuzumab for 12 weeks as standalone for the upto 1 year every 21 days)	MEDICAL ONCOLOGY	30500	30500	30500	30500	30500	30500	30500	30500
CM0100-k-III : BREAST CANCER - Trastuzumab 4mg (First dose - only) - followed by 2mg ; (to be choosen along with Docetaxel + Cyclophosphamide package CM0100-k-I) ; Trastuzumab 4mg/kg IV ; (First dose - only to be approved with Docetaxel + Cyclophosphamide Cycle 1. Subsequent cycles - 2mg package only)	MEDICAL ONCOLOGY	30500	30500	30500	30500	30500	30500	30500	30500
CM0100-k-IV : BREAST CANCER - Trastuzumab 2mg (Subsequent doses) ; Trastuzumab 2mg/kg IV ; (to be approved weekly for 11 weeeks may overlap with Docetaxel + Cyclophosphamide Cycles 2 - 4. To be followed by Trastuzumab (6mg) package upto 1 year)	MEDICAL ONCOLOGY	11500	11500	11500	11500	11500	11500	11500	11500
CM0100-L : BREAST CANCER - Paclitaxel + Trastuzumab	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0100-L-I : BREAST CANCER - Paclitaxel - (with Trastuzumab) ; (To be choosen along with Trastuzumab package - CM0100-L-III or CM0100-L-IV) ; Paclitaxel 80mg/m2 IV. ; Repeat Cycle weekly for 12 weeks.	MEDICAL ONCOLOGY	3000	3000	3000	3000	3000	3000	3000	3000
CM0100-L-II : BREAST CANCER - Trastuzumab (6mg) ; trastuzumab 6mg/kg IV ; Repeat every 21 days ; (to be approved after completion of weekly trastuzumab for 12 weeks as standalone for the upto 1 year every 21 days)	MEDICAL ONCOLOGY	30500	30500	30500	30500	30500	30500	30500	30500
CM0100-L-III : BREAST CANCER - Trastuzumab 4mg (First dose - only) - followed by 2mg ; (to be choosen along with Paclitaxel package CM0100-L-I) ; Trastuzumab 4mg/kg IV with first dose of paclitaxel. ; (First dose - only to be approved with Paclitaxel Cycle 1. Subsequent cycles - 2mg package only)	MEDICAL ONCOLOGY	30500	30500	30500	30500	30500	30500	30500	30500
CM0100-L-IV : BREAST CANCER - Trastuzumab 2mg (Subsequent doses) ; (to be choosen along with Paclitaxel package CM0100-L-I) ; Day 1: Trastuzumab 2mg/kg IV weekly ; (to be approved with Paclitaxel Cycles 2 - 12. May be approved as standalone for the upto 1 year every week or Trastuzumab 6mg Package may be used once every 21 days upto 1 year)	MEDICAL ONCOLOGY	11500	11500	11500	11500	11500	11500	11500	11500
CM0100-M : BREAST CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) ; (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0101 : BLADDER CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0101-a-I : BLADDER CANCER - DDMVAC ; Day 1: Methotrexate 30mg/m2 IV; Day 2: Vinblastine 3mg/m2 IV, doxorubicin 30mg/m2 IV, cisplatin 70mg/m2 IV; ; Repeat every 2 weeks for 3-4 cycles	MEDICAL ONCOLOGY	3800	3800	3800	3800	3800	3800	3800	3800
CM0101-a-II : BLADDER CANCER - Gemcitabine + cisplatin ; Days 1, 8, and 15: Gemcitabine 1,000mg/m2 IV; Day 2: Cisplatin 70mg/m2. ; Repeat every 4 weeks for 4 cycles.	MEDICAL ONCOLOGY	6400	6400	6400	6400	6400	6400	6400	6400
CM0101-a-III : BLADDER CANCER - Cisplatin + methotrexate + vinblastine (CMV) ; Day 1: Methotrexate 30mg/m2 IV, vinblastine 4mg/m2 IV; Day 2: Cisplatin 100mg/m2 IV, leucovorin 15mg oral or IV every 6 hours for 4 doses; Day 8: Methotrexate 30mg/m2 IV, vinblastine 4mg/m2 IV Day 9: Leucovorin 15mg oral every 6 hours for 4 doses ; Repeat every 3 weeks for 3 cycles.	MEDICAL ONCOLOGY	4800	4800	4800	4800	4800	4800	4800	4800
CM0101-b : BLADDER CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) ; (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0102 : LUNG CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0102-i : LUNG CANCER - Mesothelioma	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0102-i-a : LUNG CANCER - Mesothelioma - Pemetrexed + cisplatin ; Day 1: Pemetrexed 500mg/m2 IV, cisplatin 75mg/m2 ; Repeat every 21 days up to 12 cycles.	MEDICAL ONCOLOGY	14500	14500	14500	14500	14500	14500	14500	14500
CM0102-i-b : LUNG CANCER - Mesothelioma - Pemetrexed + carboplatin ; Day 1: Pemetrexed 500mg/m2 IV, carboplatin AUC 5mg/min/mL IV. ; Repeat every 21 days for a max of 9 cycles.	MEDICAL ONCOLOGY	16500	16500	16500	16500	16500	16500	16500	16500
CM0102-i-c : LUNG CANCER - Mesothelioma - Cisplatin & Gemcitabine ; Day 1: Cisplatin 80-100mg/m2 IV ; Days 1, 8, and 15: Gemcitabine 1000-1250mg/m2 IV ; Repeat every 21 - 28 days for 6 cycles.	MEDICAL ONCOLOGY	7600	7600	7600	7600	7600	7600	7600	7600
CM0102-i-d : LUNG CANCER - Mesothelioma - Vinorelbine ; Vinorelbine 25-30mg/m2 (max 60mg) IV ; Repeat every week for 12 weeks.	MEDICAL ONCOLOGY	9000	9000	9000	9000	9000	9000	9000	9000
CM0102-i-e : LUNG CANCER - Mesothelioma - Pemetrexed ; Day 1: Pemetrexed 500mg/m2 IV. ; Repeat every 21 days for 4 cycles (If First line) or Repeat every 21 days for 8 cycles (If Second line)	MEDICAL ONCOLOGY	14500	14500	14500	14500	14500	14500	14500	14500
CM0102-i-f : LUNG CANCER - Mesothelioma - Gemcitabine ; Days 1, 8, and 15: Gemcitabine 1250mg/m2 IV. ; Repeat every 28 days for a max of 10 cycles.	MEDICAL ONCOLOGY	7600	7600	7600	7600	7600	7600	7600	7600
CM0102-i-g : LUNG CANCER - Mesothelioma - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) ; (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0102-ii : LUNG CANCER - NSCLC	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0102-ii-a : LUNG CANCER - NSCLC - Cisplatin & Vinorelbine - (i) ; Days 1 and 8: Cisplatin 50mg/m2 IV and Days 1, 8, 15 and 22: Vinorelbine 25mg/m2 IV ; (or) ; Day 1: Cisplatin 100mg/m2 IV and Days 1, 8, 15 and 22: Vinorelbine 30mg/m2 IV. ; Repeat cycle every 4 weeks for 4 cycles.	MEDICAL ONCOLOGY	33600	33600	33600	33600	33600	33600	33600	33600
CM0102-ii-b : LUNG CANCER - NSCLC - Cisplatin & Vinorelbine - (ii) ; Day 1: Cisplatin 75-80mg/m2 ; Days 1 and 8: Vinorelbine 25-30mg/m2. ; Repeat every 3 weeks for 4 cycles	MEDICAL ONCOLOGY	17900	17900	17900	17900	17900	17900	17900	17900
CM0102-ii-c : LUNG CANCER - NSCLC - Cisplatin & Etoposide ; Day 1: Cisplatin 100mg/m2 IV ; Days 1-3: Etoposide 100mg/m2 IV. ; Repeat cycle every 4 weeks for 4 cycles	MEDICAL ONCOLOGY	4900	4900	4900	4900	4900	4900	4900	4900
CM0102-ii-d : LUNG CANCER - NSCLC - Cisplatin & Docetaxel ; Day 1: Docetaxel 75mg/m2 IV, cisplatin 75mg/m2 IV. ; Repeat every 3 weeks for 4 cycles.	MEDICAL ONCOLOGY	6300	6300	6300	6300	6300	6300	6300	6300
CM0102-ii-e : LUNG CANCER - NSCLC - Cisplatin & Gemcitabine ; Day 1: Cisplatin 75mg/m2 IV ; Days 1 and 8: Gemcitabine 1,250mg/m2 IV. ; Repeat every 3 weeks for 4 cycles	MEDICAL ONCOLOGY	6100	6100	6100	6100	6100	6100	6100	6100
CM0102-ii-f : LUNG CANCER - NSCLC - Pemetrexed + cisplatin (for Non Squamous Cell CA) ; Day 1: Cisplatin 75mg/m2 IV, pemetrexed 500mg/m2 IV. ; Repeat every - 21 days for 4 cycles.	MEDICAL ONCOLOGY	14500	14500	14500	14500	14500	14500	14500	14500
CM0102-ii-g : LUNG CANCER - NSCLC - Paclitaxel/Carboplatin ; Day 1: Paclitaxel 200mg/m2 IV, carboplatin AUC 6mg per min/mL IV. ; Repeat cycle every 3 weeks for 4 cycles.	MEDICAL ONCOLOGY	8100	8100	8100	8100	8100	8100	8100	8100
CM0102-ii-h : LUNG CANCER - NSCLC - Cisplatin & Etoposide ; Days 1, 8, 29 and 36: Cisplatin 50mg/m2 IV ; Days 1-5 and 29-33: Etoposide 50mg/m2 IV ; Concurrent thoracic radiotherapy 1.8Gy/day for 5 days/week (total dose, 61Gy).	MEDICAL ONCOLOGY	8500	8500	8500	8500	8500	8500	8500	8500
CM0102-ii-i : LUNG CANCER - NSCLC - Cisplatin & Vinblastine ; Days 1 and 29: Cisplatin 100mg/m2 IV ; Days 1, 8, 15, 22 and 29: Vinblastine 5mg/m2 IV ; concurrent thoracic radiotherapy (total dose, 60Gy).	MEDICAL ONCOLOGY	8200	8200	8200	8200	8200	8200	8200	8200
CM0102-ii-j : LUNG CANCER - NSCLC - Carboplatin + Pemetrexed ; Day 1: Carboplatin AUC 5mg per min/mL IV ; Day 1: Pemetrexed 500 mg/m2 IV ; with concurrent thoracic radiotherapy. ; Repeat every 3 weeks for 4 cycles.	MEDICAL ONCOLOGY	16500	16500	16500	16500	16500	16500	16500	16500
CM0102-ii-k : LUNG CANCER - NSCLC - Cisplatin + Pemetrexed ; Day 1: Cisplatin 75 mg/m2 IV. ; Day 1: Pemetrexed 500 mg/m2 IV ; with concurrent thoracic radiotherapy. ; Repeat every 3 weeks for 3 cycles.	MEDICAL ONCOLOGY	14900	14900	14900	14900	14900	14900	14900	14900
CM0102-ii-l : LUNG CANCER - NSCLC - Paclitaxel + Carboplatin ; Paclitaxel 45mg/m2 IV + carboplatin AUC 2mg per min/mL IV ; with concurrent thoracic radiotherapy (total dose, 60Gy) ; Repeat weekly for 6 weeks	MEDICAL ONCOLOGY	3300	3300	3300	3300	3300	3300	3300	3300
CM0102-ii-m : LUNG CANCER - NSCLC - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0102-iii : LUNG CANCER - SCLC	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0102-iii-a : LUNG CANCER - SCLC - Cisplatin & Etoposide ; Day 1: Cisplatin 60mg/m2 IV, Days 1-3: Etoposide 120mg/m2 IV. ; Repeat cycle every 3 weeks for at least 4 cycles. ;(OR) ; Day 1: Cisplatin 80mg/m2 IV, Days 1-3: Etoposide 100mg/m2 IV. ; Repeat cycle every 4 weeks for 4-6 cycles.	MEDICAL ONCOLOGY	4900	4900	4900	4900	4900	4900	4900	4900
CM0102-iii-b : LUNG CANCER - SCLC - Carboplatin & Etoposide ; Day 1: Carboplatin AUC 5-6mg per min/mL IV ; Days 1-3: Etoposide 100mg/m2 IV. ; Repeat cycle every 21 days or 28 days for 4 - 6 cycles	MEDICAL ONCOLOGY	6500	6500	6500	6500	6500	6500	6500	6500
CM0102-iii-c : LUNG CANCER - SCLC - Cisplatin + Irinotecan ; Day 1: Cisplatin 60mg/m2 IV. ; Days 1, 8, and 15: Irinotecan 60mg/m2 IV. ; Repeat cycle every 4 weeks for 4 cycles.	MEDICAL ONCOLOGY	5800	5800	5800	5800	5800	5800	5800	5800
CM0102-iii-d : LUNG CANCER - SCLC - Cisplatin + Irinotecan ; Day 1 and 8: Cisplatin 30mg/m2 IV, irinotecan 65mg/m2 IV. ; Repeat cycle every 3 weeks for 4-6 cycles.	MEDICAL ONCOLOGY	5700	5700	5700	5700	5700	5700	5700	5700
CM0102-iii-e : LUNG CANCER - SCLC - Carboplatin & Irinotecan ; Day 1: Carboplatin AUC 5mg per min/mL IV ; Days 1, 8, and 15: Irinotecan 50mg/m2 IV. ; Repeat cycle every 4 weeks for 4 cycles	MEDICAL ONCOLOGY	7700	7700	7700	7700	7700	7700	7700	7700
CM0102-iii-f : LUNG CANCER - SCLC - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) ; (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0103-i : ESOPHAGEAL CANCER - Neo Adjuvant	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0103-i-a : ESOPHAGEAL CANCER - Neo Adjuvant - Paclitaxel + Carboplatin ; Day 1: Paclitaxel 50mg/m2 IV + carboplatin AUC 2mg/min/mL IV. ; Repeat weekly for 5 weeks	MEDICAL ONCOLOGY	3300	3300	3300	3300	3300	3300	3300	3300
CM0103-i-b : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil & Cisplatin ; Days 1 and 29: Cisplatin 75-100mg/m2 IV ; Days 1-4 and 29-32: 5-FU 750-1,000mg/m2 IV.	MEDICAL ONCOLOGY	12000	12000	12000	12000	12000	12000	12000	12000
CM0103-i-c : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil & Cisplatin ; Days 1-5: Cisplatin 15mg/m2 IV daily ; Days 1-5 and Days 22-26: 5-FU 800 mg/m2 IV ; Repeat every 21 days for 2 cycles	MEDICAL ONCOLOGY	7100	7100	7100	7100	7100	7100	7100	7100
CM0103-i-d : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil + Oxaliplatin + Leucovorin ; Day 1: Oxaliplatin 85mg/m2, leucovorin 200mg/m2 and 5-FU 400mg/m2 bolus, with 1,600mg/m2 infusion; ; Repeat every 14 days for 6 cycles	MEDICAL ONCOLOGY	4600	4600	4600	4600	4600	4600	4600	4600
CM0103-i-e : ESOPHAGEAL CANCER - Neo Adjuvant - Cisplatin + capecitabine ; Day 1: Cisplatin 30mg/m2 IV ; Days 1-5: Capecitabine 800mg/m2 orally twice daily ; Repeat cycle weekly for 5 weeks	MEDICAL ONCOLOGY	2500	2500	2500	2500	2500	2500	2500	2500
CM0103-i-f : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil & Oxaliplatin ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-33: 5-FU 180mg/m2/day IV	MEDICAL ONCOLOGY	25800	25800	25800	25800	25800	25800	25800	25800
CM0103-i-g : ESOPHAGEAL CANCER - Neo Adjuvant - Oxaliplatin + capecitabine ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-5: Capecitabine 625mg/m2 orally twice daily for 5 weeks.	MEDICAL ONCOLOGY	8900	8900	8900	8900	8900	8900	8900	8900
CM0103-i-h : ESOPHAGEAL CANCER - Neo Adjuvant - Irinotecan & Cisplatin ; Days 1, 8, 22, and 29: Irinotecan 65mg/m2 IV, cisplatin 30mg/m2 IV.	MEDICAL ONCOLOGY	9700	9700	9700	9700	9700	9700	9700	9700
CM0103-i-i : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil & Paclitaxel ; Day 1: Paclitaxel 45mg/m2 IV ; Days 1-5: 5-FU 300mg/m2/day IV infusion. ; Repeat cycle weekly for 5 weeks.	MEDICAL ONCOLOGY	5500	5500	5500	5500	5500	5500	5500	5500
CM0103-i-j : ESOPHAGEAL CANCER - Neo Adjuvant - Paclitaxel + capecitabine ; Day 1: Paclitaxel 45-50mg/m2 IV ; Days 1-5: Capecitabine 625-825mg/m2 orally twice daily. ; Repeat cycle weekly for 5 weeks.	MEDICAL ONCOLOGY	12200	12200	12200	12200	12200	12200	12200	12200
CM0103-i-k : ESOPHAGEAL CANCER - Neo Adjuvant - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0103-ii : ESOPHAGEAL CANCER - Peri-Operative	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0103-ii-a : ESOPHAGEAL CANCER - Peri-Operative - ECF (Epirubicin/Cisplatin/Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV; cisplatin 60mg/m2 IV ; Days 1-21: 5-FU 200mg/m2 IV continuous infusion once daily; ; Repeat every 21 days for 3 cycles preoperatively and 3 cycles postoperatively	MEDICAL ONCOLOGY	16700	16700	16700	16700	16700	16700	16700	16700
CM0103-ii-b : ESOPHAGEAL CANCER - Peri-Operative - EOF (Epirubicin/Cisplatin/Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV; oxaliplatin 130mg/m2 IV ; Days 1-21: 5-FU 200mg/m2 IV; ; Repeat every 21 days for 3 cycles preoperatively and 3 cycles postoperatively.	MEDICAL ONCOLOGY	18700	18700	18700	18700	18700	18700	18700	18700
CM0103-ii-c : ESOPHAGEAL CANCER - Peri-Operative - EOC (Epirubicin/Cisplatin/Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV; oxaliplatin 130mg/m2 IV ; Days 1-21: Capecitabine 625mg/m2 orally twice daily. ; Repeat every 21 days for 3 cycles preoperatively and 3 cycles postoperatively.	MEDICAL ONCOLOGY	7800	7800	7800	7800	7800	7800	7800	7800
CM0103-ii-d : ESOPHAGEAL CANCER - Peri-Operative - Fluorouracil & Cisplatin ; Days 1 and 29: Cisplatin 75-100mg/m2 IV ; Days 1-4 and 29-32: 5-FU 750-1,000mg/m2 IV ; Repeat cycle every 28 days for 2-4 cycles	MEDICAL ONCOLOGY	12000	12000	12000	12000	12000	12000	12000	12000
CM0103-ii-e : ESOPHAGEAL CANCER - Peri-Operative - Fluorouracil & Cisplatin ; Days 1-5: Cisplatin 15mg/m2 IV daily ; Days 1-5: 5-FU 800 mg/m2 IV continuous infusion over 24 hours. ; Cycled every 21 days for 2 cyclesCycled every 21 days for 2 cycles	MEDICAL ONCOLOGY	7100	7100	7100	7100	7100	7100	7100	7100
CM0103-ii-f : ESOPHAGEAL CANCER - Peri-Operative - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0103-iii : ESOPHAGEAL CANCER - Post-Operative	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0103-iii-a : ESOPHAGEAL CANCER - Post-Operative - Fluorouracil + Leucovorin (i) ; Days 1-5: 5-FU 425mg/m2/day IV and leucovorin 20mg/m2/day IV, followed by 4 weeks break and CCRT ; RT Days 1-4 and 23-25: 5-FU 400mg/m2/day IV and leucovorin 20mg/m2/day IV followed by one month Break and ; Days 1-5: 5-FU 425mg/m2/day IV and leucovorin 20mg/m2/day IV followed by one month Break and ; Days 1-5: 5-FU 425mg/m2/day IV and leucovorin 20mg/m2/day IV.	MEDICAL ONCOLOGY	25400	25400	25400	25400	25400	25400	25400	25400
CM0103-iii-b : ESOPHAGEAL CANCER - Post-Operative - Fluorouracil + Leucovorin (ii) ; Days 1, 2, 15, and 16: Leucovorin 200mg/m2 IV, 5-FU 400mg/m2 IV push and 5-FU 600mg/m2 infusion	MEDICAL ONCOLOGY	9000	9000	9000	9000	9000	9000	9000	9000
CM0103-iii-c : ESOPHAGEAL CANCER - Post-Operative - Capecitabine (i) ; Days 1-14: Capecitabine 750-1000mg/m2 orally twice daily; ; Repeat every 28 days; 1 cycle before and 2 cycles after chemoradiation	MEDICAL ONCOLOGY	3100	3100	3100	3100	3100	3100	3100	3100
CM0103-iii-d : ESOPHAGEAL CANCER - Post-Operative - Capecitabine (ii) ; Days 1-5 OR Days 1-7: Capecitabine 625-825mg/m2 orally twice daily, ; once weekly for 5 weeks.	MEDICAL ONCOLOGY	1600	1600	1600	1600	1600	1600	1600	1600
CM0103-iii-e : ESOPHAGEAL CANCER - Post-Operative - FluorouracilDays 1-5 OR Days 1-7: 5-FU 200-250mg/m2 IV continuous infusion over 24 hours daily, ; once weekly for 5 weeks.once weekly for 5 weeks.	MEDICAL ONCOLOGY	6500	6500	6500	6500	6500	6500	6500	6500
CM0103-iii-f : ESOPHAGEAL CANCER - Post-Operative - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0103-iv : ESOPHAGEAL CANCER - Definitive	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0103-iv-a : ESOPHAGEAL CANCER - Definitive - Fluorouracil & Cisplatin (i) ; Days 1 and 29: Cisplatin 75-100mg/m2 IV ; Days 1-4 and 29-32: 5-FU 750-1,000mg/m2 IV	MEDICAL ONCOLOGY	12000	12000	12000	12000	12000	12000	12000	12000
CM0103-iv-b : ESOPHAGEAL CANCER - Definitive - Fluorouracil & Cisplatin (ii) ; Days 1-5: Cisplatin 15mg/m2 IV daily ; Days 1-5: 5-FU 800 mg/m2 IV continuous infusion over 24 hours. ; Cycled every 21 days for 2 cycles	MEDICAL ONCOLOGY	7100	7100	7100	7100	7100	7100	7100	7100
CM0103-iv-c : ESOPHAGEAL CANCER - Definitive - Fluorouracil & Oxaliplatin ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-33: 5-FU 180mg/m2/day continuous IV infusion.	MEDICAL ONCOLOGY	25800	25800	25800	25800	25800	25800	25800	25800
CM0103-iv-d : ESOPHAGEAL CANCER - Definitive - Cisplatin + capecitabine ; Day 1: Cisplatin 30mg/m2 IV ; Days 1-5: Capecitabine 800mg/m2 orally twice daily ; Repeat cycle weekly for 5 weeks	MEDICAL ONCOLOGY	2000	2000	2000	2000	2000	2000	2000	2000
CM0103-iv-e : ESOPHAGEAL CANCER - Definitive - Oxaliplatin + capecitabine ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-5: Capecitabine 625mg/m2 orally twice daily for 5 weeks	MEDICAL ONCOLOGY	8900	8900	8900	8900	8900	8900	8900	8900
CM0103-iv-f : ESOPHAGEAL CANCER - Definitive - Paclitaxel + Carboplatin ; Day 1: Paclitaxel 50mg/m2 IV and carboplatin 2mg/min/mL IV ; Repeat weekly for 5 weeks.	MEDICAL ONCOLOGY	3300	3300	3300	3300	3300	3300	3300	3300
CM0103-iv-g : ESOPHAGEAL CANCER - Definitive - Cisplatin with Docetaxel (i) ; Days 1 and 22: Docetaxel 60mg/m2 IV ; Days 1 and 22: Cisplatin 60-80mg/m2 IV given for 1 cycle	MEDICAL ONCOLOGY	8900	8900	8900	8900	8900	8900	8900	8900
CM0103-iv-h : ESOPHAGEAL CANCER - Definitive - Cisplatin with Docetaxel (ii) ; Day 1: Docetaxel 20-30mg/m2 IV ; Day 1: Cisplatin 20-30mg/m2 IV ; Repeat weekly for 5 weeks	MEDICAL ONCOLOGY	3000	3000	3000	3000	3000	3000	3000	3000
CM0103-iv-i : ESOPHAGEAL CANCER - Definitive - Cisplatin with Paclitaxel ; Days 1, 8, 15, and 22: Paclitaxel 60mg/m2 IV ; Day 1: Cisplatin 75mg/m2 IV given for 1 cycle.	MEDICAL ONCOLOGY	13100	13100	13100	13100	13100	13100	13100	13100
CM0103-iv-j : ESOPHAGEAL CANCER - Definitive - Irinotecan & Cisplatin ; Days 1, 8, 22, and 29: Irinotecan 65mg/m2 IV ; Days 1, 8, 22, and 29: Cisplatin 30mg/m2 IV.	MEDICAL ONCOLOGY	9700	9700	9700	9700	9700	9700	9700	9700
CM0103-iv-k : ESOPHAGEAL CANCER - Definitive - Fluorouracil & Paclitaxel ; Day 1: Paclitaxel 45mg/m2 IV ; Days 1-5: 5-FU 300mg/m2/day IV ; Repeat cycle weekly for 5 weeks.	MEDICAL ONCOLOGY	5500	5500	5500	5500	5500	5500	5500	5500
CM0103-iv-l : ESOPHAGEAL CANCER - Definitive - Paclitaxel + capecitabine ; Day 1: Paclitaxel 45-50mg/m2 IV ; Days 1-5: Capecitabine 625-825mg/m2 PO twice daily. ; Repeat cycle weekly for 5 weeks.	MEDICAL ONCOLOGY	12200	12200	12200	12200	12200	12200	12200	12200
CM0103-iv-m : ESOPHAGEAL CANCER - Definitive - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0104 : GASTRIC CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0104-i : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0104-i-a : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Paclitaxel + Carboplatin ; Day 1: Paclitaxel 50mg/m2 IV, carboplatin AUC 2mg/min/mL IV. ; Repeat cycle weekly for 5 weeks.	MEDICAL ONCOLOGY	3300	3300	3300	3300	3300	3300	3300	3300
CM0104-i-b : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Cisplatin (i) ; Days 1 and 29: Cisplatin 75-100mg/m2 IV ; Days 1-4 and 29-32: 5-FU 750-1000mg/m2/day IV	MEDICAL ONCOLOGY	12000	12000	12000	12000	12000	12000	12000	12000
CM0104-i-c : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Cisplatin (ii) ; Days 1-5: Cisplatin 15mg/m2 IV once daily, 5-FU 800mg/m2/day IV ; Repeat cycle every 21 days for 2 cycles.	MEDICAL ONCOLOGY	7100	7100	7100	7100	7100	7100	7100	7100
CM0104-i-d : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Oxaliplatin (i)Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-33: 5-FU 180mg/m2/day IV.	MEDICAL ONCOLOGY	25800	25800	25800	25800	25800	25800	25800	25800
CM0104-i-e : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Oxaliplatin (ii)Day 1: Oxaliplatin 85mg/m2 and leucovorin 400mg/m2 followed by 5-FU 400mg/m2 bolus, then 800mg/m2 24-hour continuous infusion over days 1 and 2; the first 3 cycles were delivered during radiotherapy (RT), the other 3 after RT; 6 bimonthly (14 days) cycles.	MEDICAL ONCOLOGY	6100	6100	6100	6100	6100	6100	6100	6100
CM0104-i-f : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Cisplatin + capecitabine ; Day 1: Cisplatin 30mg/m2 IV ; Days 1-5: Capecitabine 800mg/m2 orally twice daily. ; Repeat cycle weekly for 5 weeks.	MEDICAL ONCOLOGY	2000	2000	2000	2000	2000	2000	2000	2000
CM0104-i-g : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Oxaliplatin + capecitabine ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-5: Capecitabine 625mg/m2 orally twice daily for 5 weeks	MEDICAL ONCOLOGY	8900	8900	8900	8900	8900	8900	8900	8900
CM0104-i-h : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Paclitaxel ; Day 1: Paclitaxel 45-50mg/m2 IV weekly ; Days 1-5: 5-FU 300mg/m2 IV ; Repeat cycle weekly for 5 weeks	MEDICAL ONCOLOGY	5500	5500	5500	5500	5500	5500	5500	5500
CM0104-i-i : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Paclitaxel + capecitabine ; Day 1: Paclitaxel 45-50mg/m2 IV ; Days 1-5: Capecitabine 625-825mg/m2 orally twice daily. ; Repeat cycle weekly for 5 weeks.	MEDICAL ONCOLOGY	3100	3100	3100	3100	3100	3100	3100	3100
CM0104-i-j : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0104-ii : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0104-ii-a : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - ECF (Epirubicin/Cisplatin/Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV, cisplatin 60mg/m2 IV ; Days 1-21: 5-FU 200mg/m2/day IV ; Repeat cycle every 21 days for 3 cycles preoperatively and 3 cycles postoperatively	MEDICAL ONCOLOGY	16700	16700	16700	16700	16700	16700	16700	16700
CM0104-ii-b : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - EOF (Epirubicin/ oxaliplatin /Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV; oxaliplatin 130mg/m2 IV ; Days 1-21: 5-FU 200mg/m2 IV; ; Repeat every 21 days for 3 cycles preoperatively and 3 cycles postoperatively.	MEDICAL ONCOLOGY	18700	18700	18700	18700	18700	18700	18700	18700
CM0104-ii-c : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - epirubicin + cisplatin + capecitabine ; Day 1: Epirubicin 50mg/m2 IV + cisplatin 60mg/m2 IV ; Days 1-21: Capecitabine 625mg/m2 orally twice daily. ; Repeat cycle every 21 days for 3 cycles preoperatively and 3 cycles postoperatively.	MEDICAL ONCOLOGY	5900	5900	5900	5900	5900	5900	5900	5900
CM0104-ii-d : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - ECF modification (epirubicin + oxaliplatin + capecitabine) ; Day 1: Epirubicin 50mg/m2 IV + oxaliplatin 130mg/m2 IV ; Days 1-21: Capecitabine 625mg/m2 orally twice daily. ; Repeat cycle every 21 days for 3 cycles preoperatively and 3 cycles postoperativelyRepeat cycle every 21 days for 3 cycles preoperatively and 3 cycles postoperatively	MEDICAL ONCOLOGY	7800	7800	7800	7800	7800	7800	7800	7800
CM0104-ii-e : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - Fluorouracil & Cisplatin ; Day 1: Cisplatin 75-80mg/m2 IV ; Days 1-5: 5-FU 800mg/m2 IV ; Repeat cycle every 28 days for 2-3 cycles preoperatively and 3-4 cycles postoperatively for a total of 6 cycles.	MEDICAL ONCOLOGY	6900	6900	6900	6900	6900	6900	6900	6900
CM0104-ii-f : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0104-iii : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0104-iii-a : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Fluorouracil + Leucovorin (i) ; Cycles 1, 3, and 4 (before and after radiation) Days 1-5: Leucovorin 20mg/m2 IV, 5-FU 425mg/m2/day IV ; Repeat cycle every 28 days. ; Cycle 2 (with radiation) Days 1-4 and 31-33: Leucovorin 20mg/m2 IVP ; Days 1-4: 5-FU 400mg/m2/day IVP. ; Repeat cycle every 35 days	MEDICAL ONCOLOGY	25400	25400	25400	25400	25400	25400	25400	25400
CM0104-iii-b : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Fluorouracil + Leucovorin (ii) ; Days 1, 2, 15, and 16: Leucovorin 400mg/m2 IV, 5-FU 400mg/m2 IV and 5-FU 1200mg/m2 infusion; ; 1 cycle before and 2 cycles after chemoradiation. ; Repeat cycle every 28 daysRepeat cycle every 28 days	MEDICAL ONCOLOGY	14900	14900	14900	14900	14900	14900	14900	14900
CM0104-iii-c : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Capecitabine (i) ; Days 1-14: Capecitabine 750-1000mg/m2 orally twice daily. ; Repeat cycle every 28 days; 1 cycle before and 2 cycles after chemoradiation.	MEDICAL ONCOLOGY	3100	3100	3100	3100	3100	3100	3100	3100
CM0104-iii-d : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Capecitabine (ii) ; Days 1-5 OR Days 1-7: Capecitabine 625-825mg/m2 orally twice daily; weekly for 5 weeks.	MEDICAL ONCOLOGY	1600	1600	1600	1600	1600	1600	1600	1600
CM0104-iii-e : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Fluorouracil ; Days 1-5 OR Days 1-7: 5-FU 200-250mg/m2 IV; ; weekly for 5 weeks.	MEDICAL ONCOLOGY	6500	6500	6500	6500	6500	6500	6500	6500
CM0104-iii-f : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Cisplatin + capecitabine ; Day 1: Cisplatin 60mg/m2 IV. ; Days 1-14: Capecitabine 1000mg/m2 orally twice daily ; Repeat cycle every 21 days for 6 cycles.	MEDICAL ONCOLOGY	4000	4000	4000	4000	4000	4000	4000	4000
CM0104-iii-h : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Oxaliplatin + capecitabine ; Day 1: Oxaliplatin 130mg/m2 IV. ; Days 1-14: Capecitabine 1000mg/m2 orally twice daily ; Repeat cycle every 21 days for 8 cycles.Repeat cycle every 21 days for 8 cycles.	MEDICAL ONCOLOGY	6000	6000	6000	6000	6000	6000	6000	6000
CM0104-iii-i : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0105-i : COLORECTAL CARCINOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0105-i-a : COLORECTAL CARCINOMA - FOLFOX (Stage - III) - (Oxaliplatin, Leucovorin, 5-FU) ; Day 1: Oxaliplatin 85mg/m2 IV, leucovorin 400mg/m2 IV , 5-FU 400mg/m2 IV, followed by 5-FU 1,200mg/m2/day IV x 2 days (total 2,400mg/m2) over 46-48-hour continuous infusion. ; Repeat cycle every 2 weeks- upto 12 cycles	MEDICAL ONCOLOGY	8000	8000	8000	8000	8000	8000	8000	8000
CM0105-i-b : COLORECTAL CARCINOMA - CAPEOX (Stage - III) (Oxaliplatin, Capecitabine) ; Day 1: Oxaliplatin 130mg/m2 IV over 2 hours ; Days 1-14: Capecitabine 1,000mg/m2 orally twice daily. ; Repeat cycle every 3 weeks for 6 months	MEDICAL ONCOLOGY	6500	6500	6500	6500	6500	6500	6500	6500
CM0105-i-c : COLORECTAL CARCINOMA - FLOX (Stage - III) (5-FU, leucovorin, oxaliplatin) ; 5-FU 500mg/m2 IV bolus weekly x 6, leucovorin 500mg/m2 IV weekly x 6, each ; oxaliplatin 85mg/m2 IV on weeks 1, 3, and 5 ; 8-week cycle x 3 cycles ;	MEDICAL ONCOLOGY	30000	30000	30000	30000	30000	30000	30000	30000
CM0105-i-d : COLORECTAL CARCINOMA - Capecitabine ; Capecitabine 1,250mg/m2 - BD / TDS D 1-14 ; every 3 weeks * 24 weeks	MEDICAL ONCOLOGY	4300	4300	4300	4300	4300	4300	4300	4300
CM0105-i-e : COLORECTAL CARCINOMA - Fluorouracil + Leucovorin (i) ; Leucovorin 500mg/m2 weekly x 6 weeks, ; 5-FU 500mg/m2 weekly x 6 weeks. ; Repeat cycle every 8 weeks for 4 cycles.	MEDICAL ONCOLOGY	23700	23700	23700	23700	23700	23700	23700	23700
CM0105-i-f : COLORECTAL CARCINOMA - Fluorouracil + Leucovorin (ii)Simplified biweekly infusion. ; Leucovorin 400mg/m2 IV, 5-FU bolus 400mg/m2 and then 1,200mg/m2/day x 2 days (total 2,400mg/m2 over 46-48 hours) ; Repeat cycle every 2 weeks for 6 cycles.	MEDICAL ONCOLOGY	5200	5200	5200	5200	5200	5200	5200	5200
CM0105-i-g : COLORECTAL CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0105-ii : COLORECTAL CARCINOMA - Concurrent	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0105-ii-a : COLORECTAL CARCINOMA - Concurrent - 5FU - with XRT ; Days 1-5 OR 1-7: 5-FU 225mg/m2 IV ; with External beam radiotherapy	MEDICAL ONCOLOGY	3800	3800	3800	3800	3800	3800	3800	3800
CM0105-ii-b : COLORECTAL CARCINOMA - Concurrent - Fluorouracil + Leucovorin - with XRT ; Days 1-4: 5-FU 400mg/m2 IV + leucovorin 20mg/m2 IV. ; Repeat cycle during weeks 1 and 5 of XRT.	MEDICAL ONCOLOGY	6100	6100	6100	6100	6100	6100	6100	6100
CM0105-ii-c : COLORECTAL CARCINOMA - Concurrent - Capecitabine - with XRT ; Capecitabine Tablet 825mg / m2 twice daily on Days 1-5 ; Repeat cycle weekly for 5 weeks.	MEDICAL ONCOLOGY	1300	1300	1300	1300	1300	1300	1300	1300
CM0105-ii-d : COLORECTAL CARCINOMA - Concurrent - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0106-106 : OSTEOSARCOMA/ BONE TUMORS	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0106-i-a : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - Cisplatin + doxorubicin ; Days 1-3: Doxorubicin 25mg/m2/day IV, ; Day 1: Cisplatin 100mg/m2 IV ; Repeat cycle every 3 weeks for 6 cycles	MEDICAL ONCOLOGY	5600	5600	5600	5600	5600	5600	5600	5600
CM0106-i-b-1 : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - MAP (high-dose methotrexate + cisplatin + doxorubicin) - PRE OPERATIVE ; Days 1 and 28: Methotrexate 8g/m2 IV ; Days 7-9 and 34-36: Cisplatin 120mg/m2 by infusion for 72 hours. ; Days 9 and 36: Doxorubicin 60mg/m2 IV	MEDICAL ONCOLOGY	24200	24200	24200	24200	24200	24200	24200	24200
CM0106-i-b-2 : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - MAP (high-dose methotrexate + cisplatin + doxorubicin) - POST OPERATIVE NECROSIS < 90% ; Days 1, 48, 96, and 144: Doxorubicin 45mg/m2/day for 2 consecutive days ; Days 21, 69, and 117: Methotrexate 8g/m2 IV ; Days 27, 75, and 123: Cisplatin 120mg/m2 by infusion for 72 hours.	MEDICAL ONCOLOGY	40100	40100	40100	40100	40100	40100	40100	40100
CM0106-i-b-3 : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - MAP (high-dose methotrexate + cisplatin + doxorubicin) - POST OPERATIVE NECROSIS > 90%Postoperative Chemotherapy (Necrosis <90%) ; Days 1, 69, 138, and 207: Doxorubicin 45mg/m2/day for 2 consecutive days ; Days 21, 90, and 159: Ifosfamide 2g/m2/day IV for 5 consecutive days + mesna ; Days 42, 111, and 180: Methotrexate 8g/m2 IV ; Days 48, 117, and 186: Etoposide 120mg/m2/day for 3 days.	MEDICAL ONCOLOGY	59100	59100	59100	59100	59100	59100	59100	59100
CM0106-i-c : Doxorubicin + cisplatin + ifosfamide + high-dose methotrexate (surgery to be done also)	MEDICAL ONCOLOGY	111505	111505	111505	111505	111505	111505	111505	111505
CM0106-i-d : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - Ifosfamide + cisplatin + epirubicin ; Day 1: Epirubicin 90mg/m2 IV, cisplatin 100mg/m2 IV ; Days 2-4: Ifosfamide 2.0g/m2 with mesna ; Repeat cycle every 21 days. (3 cycles preoperatively and 3 cycles postoperatively).	MEDICAL ONCOLOGY	8300	8300	8300	8300	8300	8300	8300	8300
CM0106-ii : Other bone tumors - Chordroma	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0106-ii-a : Other bone tumors - Chordroma - Imatinib ; Imatinib 800 mg once daily	MEDICAL ONCOLOGY	4500	4500	4500	4500	4500	4500	4500	4500
CM0106-ii-b : Other bone tumors - Chordroma - Imatinib + cisplatin ; Imatinib 400mg OD + cisplatin 25mg/m2 weekly.	MEDICAL ONCOLOGY	4500	4500	4500	4500	4500	4500	4500	4500
CM0106-ii-c : Other bone tumors - Chordroma - Imatinib + sirolimus ; Imatinib 400mg OD + sirolimus 2mg OD	MEDICAL ONCOLOGY	6000	6000	6000	6000	6000	6000	6000	6000
CM0106-ii-d : Other bone tumors - Chordroma - Erlotinib ; Erlotinib 150mg OD	MEDICAL ONCOLOGY	2200	2200	2200	2200	2200	2200	2200	2200
CM0106-ii-e : Other bone tumors - Chordroma - Sunitinib ; Sunitinib 37.5mg OD	MEDICAL ONCOLOGY	28500	28500	28500	28500	28500	28500	28500	28500
CM0106-iii :Other bone tumors - Giant Cell Tumor of Bone	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0106-iii-a :Other bone tumors - Giant Cell Tumor of Bone - Denosumab ; Denosumab 120mg subcutaneous on Week 1,2 and 3 of a 4 week cycle	MEDICAL ONCOLOGY	56000	56000	56000	56000	56000	56000	56000	56000
CM0106-iii-b :Other bone tumors - Giant Cell Tumor of Bone - Interferon alfa ; interferon alfa- 2a thrice weekly	MEDICAL ONCOLOGY	4600	4600	4600	4600	4600	4600	4600	4600
CM0106-iii-c :Other bone tumors - Giant Cell Tumor of Bone - Peginterferon ; Peginterferon alfa-2a 1.0mcg/kg SQ injection weekly.	MEDICAL ONCOLOGY	3500	3500	3500	3500	3500	3500	3500	3500
CM0106-iv : Other bone tumors - Mesenchymal Chordosarcoma	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0106-iv-a : VAC and IE cycles	MEDICAL ONCOLOGY	6420	6420	6420	6420	6420	6420	6420	6420
CM0106-iv-b : Other bone tumors - Mesenchymal Chordosarcoma VAIA ; Day 1: Vincristine 1.5mg/m2 IV ; Days 1-3: Ifosfamide 2,000mg/m2 IV + mesna ; Days 1, 3, and 5: Dactinomycin 0.5mg/m2 IV ; Days 2 and 4: Doxorubicin 30mg/m2 IV. ; Repeat cycle every 3 weeks.	MEDICAL ONCOLOGY	7600	7600	7600	7600	7600	7600	7600	7600
CM0106-v : Other bone tumors - Mesenchymal Chordosarcoma Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0107 : WILMS TUMOR	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0107-a : WILMS TUMOR - Vincristine & Actinomycin D ; Dactinomycin 45mcg/kg - week - 0, 3, 6,9,12,15,18 ; Vincristine 1.5 mg/m2 - week - 1,2,3,4,5,6,7,8,9,10,12,15,18	MEDICAL ONCOLOGY	19400	19400	19400	19400	19400	19400	19400	19400
CM0107-b : WILMS TUMOR - Dactinomycin, Vincristine & Adriamycin ; Dactinomycin 1.35 mg /m2 - week - 0, 6, 12, 18,24 ; Adriyamycin 30-45 mg /m2- week - 3, 9, 15, 21 ; Vincristine 2mg max- week - 1,2,3,4,5,6,7,8,9,10,12,15,18,21,24	MEDICAL ONCOLOGY	23200	23200	23200	23200	23200	23200	23200	23200
CM0107-c : WILMS TUMOR - Adriamycin, Cyclophosphamide, Etoposide, Vincristine ; Cyclophosphamide 440mg/m2/day - week 3, 9, 15, 21 for 5 days, week - 6,12,18,24 for 3 days ; Adriyamycin 30-45mg /m2- week -0, 6, 12, 18,24 ; Vincristine 2mg (max)- week - 1,2,4,5,6,7,8,10,11, 12,13,18,24 ; Etoposide 100mg /m2- week - 3,9,15,21	MEDICAL ONCOLOGY	53700	53700	53700	53700	53700	53700	53700	53700
CM0107-d : WILMS TUMOR - Cyclophosphamide, Etoposide, Carboplatin ; Cyclophosphamide 440mg/m2/day - week 6,15,24 5 days / week ; Carboplatin 500mg/m2 - week - 0,3,9,12,18,21 2 days / week ; Etoposide 100mg/m2 - week - 0,3,9,12,18,21 *5 days / week	MEDICAL ONCOLOGY	84500	84500	84500	84500	84500	84500	84500	84500
CM0107-e : WILMS TUMOR - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0108 : HEPATOBLASTOMA- OPERABLEHEPATOBLASTOMA- OPERABLE	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0108-a : HEPATOBLASTOMA- OPERABLE - PLADO - Cisplatin + Doxorubicin ; cisplatin (PLA) (80mg/m2 / iv), doxorubicin (DO) (30 mg/m2 IV ; Every 21 days for 6 cycles	MEDICAL ONCOLOGY	2800	2800	2800	2800	2800	2800	2800	2800
CM0108-b : HEPATOBLASTOMA- OPERABLE - Cisplatin + Vincristine +5FU ; cisplatin (90 mg/m2), vincristine (1.5mg/m2), 5-FU(5-Flurouracil- 600 mg/m2) ; Every 21 days for 6 cycles	MEDICAL ONCOLOGY	2400	2400	2400	2400	2400	2400	2400	2400
CM0108-c : HEPATOBLASTOMA- OPERABLE - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0109 : HEPATOCELLULAR CARCINOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0109-a : HEPATOCELLULAR CARCINOMA - Sorafenib ; Sorafenib 400 mg PO BID	MEDICAL ONCOLOGY	5800	5800	5800	5800	5800	5800	5800	5800
CM0109-b : HEPATOCELLULAR CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0110A : Neuroblastoma ALL STAGES - VINCRISTINE/CISPLATIN/ETOPOSIDE/CYCLOPHOSPHAMIDE/CARBOPLATIN	MEDICAL ONCOLOGY	8000	8000	8000	8000	8000	8000	8000	8000
CM0110B : Neuroblastoma ALL STAGES - CYCLOPHOSPHAMIDE/ADRIAMYCIN/VINCRISTINE ; D1-D5 - CYCLOPHOSPHAMIDE 300mg/m2 ; ADRIAMYCIN 60mg/m2 ; VINCRISTINE 1.5mg/m2	MEDICAL ONCOLOGY	7100	7100	7100	7100	7100	7100	7100	7100
CM0110C : Neuroblastoma ALL STAGES - Cisplatin & Etoposide ; Days 1-5 : Cisplatin - 20mg/m2 ; Days 1-5 : Etoposide - 70 mg/m2	MEDICAL ONCOLOGY	4900	4900	4900	4900	4900	4900	4900	4900
CM0110D : Neuroblastoma ALL STAGES - Carboplatin & Etoposide ; Days 1-2 : Carboplatin - 500mg/m2 ; Days 1-5: Etoposide 100mg/m2	MEDICAL ONCOLOGY	6500	6500	6500	6500	6500	6500	6500	6500
CM0110E : Neuroblastoma ALL STAGES - For Stage IV Palliative Chemotherapy only	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0110F : Neuroblastoma ALL STAGES - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0111 : RETINOBLASTOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0111-a : RETINOBLASTOMA - Melphalan - Intra-arterial ; Melphalan - 3-7.5mg - Intra-arterial	MEDICAL ONCOLOGY	9700	9700	9700	9700	9700	9700	9700	9700
CM0111-b : RETINOBLASTOMA - Carboplatin - Intra-arterial ; Carboplatin 15-30 mg - Intra-arterial	MEDICAL ONCOLOGY	8900	8900	8900	8900	8900	8900	8900	8900
CM0111-c : RETINOBLASTOMA - Topotecan - Intra-arterial ; Topotecan 0.15-1.5 mg - Intra-arterial	MEDICAL ONCOLOGY	9900	9900	9900	9900	9900	9900	9900	9900
CM0111-d : RETINOBLASTOMA - Methotrexate - Intra-arterial ; Methotrexate 6-12 mg - Intra-arterial	MEDICAL ONCOLOGY	8600	8600	8600	8600	8600	8600	8600	8600
CM0111-e : RETINOBLASTOMA - Carboplatin - Peri Ocular ; Carboplatin 20mg/m2 - Peri Ocular	MEDICAL ONCOLOGY	1900	1900	1900	1900	1900	1900	1900	1900
CM0111-f : RETINOBLASTOMA - Topotecan - Peri Ocular ; Topotecan 0.09 - 0.27 - Peri Ocular	MEDICAL ONCOLOGY	4300	4300	4300	4300	4300	4300	4300	4300
CM0111-g : RETINOBLASTOMA - Melphalan - Intra-vitreal ; Melphalan 20-30 mcg / 0.1cc - Intra-vitreal	MEDICAL ONCOLOGY	270	270	270	270	270	270	270	270
CM0111-h : RETINOBLASTOMA - Carboplatin - Intra-vitreal ; Carboplatin 3-6mcg / 0.05cc - Intra-vitreal	MEDICAL ONCOLOGY	1900	1900	1900	1900	1900	1900	1900	1900
CM0111-i : RETINOBLASTOMA - Methotrexate - Intra-vitreal ; Methotrexate 400mcg/0.1cc - Intra-vitreal	MEDICAL ONCOLOGY	1600	1600	1600	1600	1600	1600	1600	1600
CM0111-j : RETINOBLASTOMA - Carboplatin + Etoposide + Vincristine ; Carboplatin 560mg/m2 ; Etoposide 150mg/m2 ; Vincristine 1.5mg/m2	MEDICAL ONCOLOGY	6800	6800	6800	6800	6800	6800	6800	6800
CM0111-k : RETINOBLASTOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0112 : HISTIOCYTOSIS	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0112-a : HISTIOCYTOSIS - Prednisolone and Vinblastine - 1; Prednisolone and Vinblastine - 1 ; Prednisolone - 6 weeks oral ; Vinblastine 1,2,3,4,5,6	MEDICAL ONCOLOGY	6100	6100	6100	6100	6100	6100	6100	6100
CM0112-b : HISTIOCYTOSIS - Prednisolone and Vinblastine - 2; Prednisolone and Vinblastine - 1 ; Prednisolone - 6 weeks oral ; Vinblastine 1,2,3,4,5,6	MEDICAL ONCOLOGY	6800	6800	6800	6800	6800	6800	6800	6800
CM0112-c : HISTIOCYTOSIS - Prednisolone and Vinblastine - continuation; Prednisolone and Vinblastine - continuation after either course 1 or both 1 & 2 ; Prednisolone - 5 days a week oral ; Vinblastine -IV ; repeat every 3 weeks till 1 year	MEDICAL ONCOLOGY	1800	1800	1800	1800	1800	1800	1800	1800
CM0112-d : HISTIOCYTOSIS - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0113 : RHABDOMYOSARCOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0113-a : RHABDOMYOSARCOMA - VAC (Vincristine + Dactinomycin + Cyclophosphamide + Mesna ) ; Day -1 - Vincristine 1.5 mg /m2 IV (2 mg max), Doxorubicin 75 mg /m2 IV , cyclophosphamide 1200 mg /m2 IV + mesna ; Repeat at 21 day intervals for 4-6 cycles	MEDICAL ONCOLOGY	3800	3800	3800	3800	3800	3800	3800	3800
CM0113-b : RHABDOMYOSARCOMA - IVA (Vincristine + Dactinomycin + Ifosfamide + Mesna ) ; Day 1,2 - Ifosfamide IV 3 g/m2 + mesna ; Day 1 - Vincristine IV 1.5 mg/m2 (max 2 mg), Actinomycin-D IV 1.5 mg/m2 (max 2 mg) ; Repeat at 21 day intervals for 6 cycles	MEDICAL ONCOLOGY	5600	5600	5600	5600	5600	5600	5600	5600
CM0113-c : RHABDOMYOSARCOMA - IVAD (Vincristine + Doxorubicin + Ifosfamide + Mesna ) ; Days 1 and 2 - Ifosfamide 3 g/m2 + Mesna, Doxorubicin 30mg/m2 ; Day 1 - vincristine 1.5 mg/m2, Actinomycin-D 1.5 mg/m2 ; Repeat at 21 day intervals for 6 cycles	MEDICAL ONCOLOGY	5500	5500	5500	5500	5500	5500	5500	5500
CM0113-d : RHABDOMYOSARCOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0114 : EWINGS SARCOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0114-i : EWINGS SARCOMA - Induction Treatment I	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0114-i-a : EWINGS SARCOMA - Induction Treatment - VIDE ; Day 1:Vincristine 1.5mg/m2(max 2mg) IV ; Days 1-3:Doxorubicin 20mg/m2 IV, ifosfamide 3g/m2IV, mesna continuous IV, etoposide 150mg/m2 IV ; Repeat cycle every 3 weeks for up to 6 cycles	MEDICAL ONCOLOGY	8300	8300	8300	8300	8300	8300	8300	8300
CM0114-i-b : EWINGS SARCOMA - Induction Treatment - VAC/IE ;	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0114-i-c : EWINGS SARCOMA - Induction Treatment - VAIA - 4 day Regimen ; Day 1:Vincristine 1.5mg/m2IV ; Days 1-3: Ifosfamide 2,000mg/m2 IV + mesna ; Days 1, 3, and 5: Dactinomycin 0.5mg/m2 IV ; Days 2 and 4: Doxorubicin 30mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles, then local therapy, followed by 10 additional cycles of VAIA for High risk and ; 10 additional cycles of VAIA or 10 cycles of VACA for standard-risk patients	MEDICAL ONCOLOGY	7600	7600	7600	7600	7600	7600	7600	7600
CM0114-i-d : EWINGS SARCOMA - Induction Treatment - VAIA - 24 day Regimen ; Days 1, 8, 15, and 22: Vincristine 1.5mg/m2 IV ; Days 1, 2, 22, 23, 43, and 44 : Ifosfamide 3,000mg/m2 IV + mesna ; Days 1, 2, 43, and 44 : Doxorubicin 30mg/m2 IV ; Days 22, 23, and 24: Dactinomycin 0.5mg/m2 IV ; After completion of one 9-week cycle, local therapy followed by 3 additional cycles.	MEDICAL ONCOLOGY	17700	17700	17700	17700	17700	17700	17700	17700
CM0114-ii : EWINGS SARCOMA - Maintenance Treatment	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0114-ii-a : EWINGS SARCOMA - Maintenance Treatment - Etoposide/Ifosfamide ; Days 1-5: Ifosfamide 1,800mg/m2/day IV + mesna ; Days 1-5: Etoposide 100mg/m2/day IV.	MEDICAL ONCOLOGY	8200	8200	8200	8200	8200	8200	8200	8200
CM0114-iii : EWINGS SARCOMA - Maintenance Treatment - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0115 : PALLIATIVE CHEMOTHERAPY (Any Regimen)- Maximum Payable	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0116 : CERVICAL CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0116-a : CERVICAL CANCER - CISPLATIN ; Cisplatin 40mg/m2 IV once weekly for up to 6 cycles	MEDICAL ONCOLOGY	1800	1800	1800	1800	1800	1800	1800	1800
CM0116-b : CERVICAL CANCER - Cisplatin & 5FU with RT ; Days 1-5 of radiotherapy: Cisplatin 75mg/m2 IV, 5-FU 4,000mg/m2 IV over 96 hours ; Repeat cycle every 3 weeks for 3	MEDICAL ONCOLOGY	9200	9200	9200	9200	9200	9200	9200	9200
CM0116-c : CERVICAL CANCER - Cisplatin & 5FU ; Days 1 and 29: Cisplatin 50mg/m2 IV ; Days 2-5, and 30-33: 5-FU 1,000mg/m2 IV	MEDICAL ONCOLOGY	8900	8900	8900	8900	8900	8900	8900	8900
CM0116-d : CERVICAL CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0117 : VULVAL CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0117-a : VULVAL CANCER - Cisplatin ; Day 1 : 40 mg/m 2 IV	MEDICAL ONCOLOGY	1800	1800	1800	1800	1800	1800	1800	1800
CM0117-b : VULVAL CANCER - Cisplatin + 5FU ; Days 1-5 of radiotherapy: Cisplatin 75mg/m2 IV, 5-FU 4,000mg/m2 ; Repeat cycle every 3 weeks - total 3 cycles	MEDICAL ONCOLOGY	4700	4700	4700	4700	4700	4700	4700	4700
CM0117-c : VULVAL CANCER - 5-FU + Mitomycin ; 5-FU + Mitomycin ; Days 1-4 and 29-32: 5-FU 1,000mg/m2/day continuous IV infusion ; Days 1 and 29: Mitomycin 10mg/m2 IV bolus (maximum 20mg per course),	MEDICAL ONCOLOGY	11400	11400	11400	11400	11400	11400	11400	11400
CM0117-d : VULVAL CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0118 : VAGINAL CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0118-a : VAGINAL CANCER - Cisplatin ; Cisplatin 75mg/m2 ; once weekly for up to 6 doses	MEDICAL ONCOLOGY	1800	1800	1800	1800	1800	1800	1800	1800
CM0118-b : VAGINAL CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0119 : OVARIAN CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0119-a : OVARIAN CANCER - Paclitaxel + Cisplatin ; Day 1: Paclitaxel 135mg/m2 continuous IV ; Day 2: Cisplatin 75-100mg/m2 ; Day 8: Paclitaxel 60mg/m2 ; Repeat every 3 weeks for 6 cycles.	MEDICAL ONCOLOGY	8800	8800	8800	8800	8800	8800	8800	8800
CM0119-b : OVARIAN CANCER - Paclitaxel + Carboplatin ; Day 1: Paclitaxel 175mg/m2 IV, Carboplatin AUC 5-6 mg/min/mL IV ; Repeat every 3 weeks for 6 cycles	MEDICAL ONCOLOGY	7000	7000	7000	7000	7000	7000	7000	7000
CM0119-c : OVARIAN CANCER - Docetaxel + Carboplatin ; Day 1: Docetaxel 60-75mg/m2 IV, Carboplatin AUC 5-6 mg/min/mL ; Repeat every 3 weeks for 6 cycles	MEDICAL ONCOLOGY	8700	8700	8700	8700	8700	8700	8700	8700
CM0119-d : OVARIAN CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0120 : ENDOMETRIAL CANCER (Palliative Chemotherapy only)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0121 : OVARY- GERM CELL TUMOR	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0121-a : OVARY- GERM CELL TUMOR - BEP (Bleomycin + Etoposide + Cisplatin) ; Days 1,8,15 : Bleomycin 30 units/wk IV, Etoposide 100 mg/m 2/day IV ; Days 1-5 : Cisplatin 20 mg/m 2/day IV ; Repeat every 21 days 3-4 cycles	MEDICAL ONCOLOGY	10800	10800	10800	10800	10800	10800	10800	10800
CM0121-b : OVARY- GERM CELL TUMOR - EP ( Etoposide + Carboplatin) ; Day 1 : Carboplatin 400 mg/m 2 IV on days 1-3 ; Repeat every 28 days for three cycles	MEDICAL ONCOLOGY	6500	6500	6500	6500	6500	6500	6500	6500
CM0121-c : OVARY- GERM CELL TUMOR - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0122 : GESTATIONAL TROPHOBLAST DISEASES	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0122-a : GESTATIONAL TROPHOBLAST DISEASES - Methotrexate (5 days regimen) ; Days 1-5: MTX 0.4 mg/kg/day IV or IM for 5 days, not to exceed 25 mg/day ; Repeat cycle every 14 days	MEDICAL ONCOLOGY	2100	2100	2100	2100	2100	2100	2100	2100
CM0122-b : GESTATIONAL TROPHOBLAST DISEASES - Methotrexate (8-day alternating regimen) ; Days 1, 3, 5, and 7 : MTX 1 mg/kg IM, ; Days 2, 4, 6, and 8 : Folinic acid 15 mg ; Repeat cycle every 14 days	MEDICAL ONCOLOGY	2900	2900	2900	2900	2900	2900	2900	2900
CM0122-c : GESTATIONAL TROPHOBLAST DISEASES - Methotrexate + Folinic Acid ; Day 1 : MTX 100 mg/m 2 IVP, then 200 mg/m 2 infusion ; Day 2 : Folinic acid 15 mg IM/PO q12h for 4 doses ; Repeat cycle every 18 days	MEDICAL ONCOLOGY	2000	2000	2000	2000	2000	2000	2000	2000
CM0122-d : GESTATIONAL TROPHOBLAST DISEASES - Methotrexate - Weekly ; MTX 30-50 mg/m 2 IM weekly	MEDICAL ONCOLOGY	1300	1300	1300	1300	1300	1300	1300	1300
CM0122-e : GESTATIONAL TROPHOBLAST DISEASES - Act-D ; Act-D 10-13 mcg/kg or 0.5-mg flat dose IV qd for 5d ; Repeat cycle every 14 days	MEDICAL ONCOLOGY	7800	7800	7800	7800	7800	7800	7800	7800
CM0122-f : GESTATIONAL TROPHOBLAST DISEASES - Actinomycin ; Actinomycin 1.25 mg/m 2 IV ; Repeat every 2 weeks	MEDICAL ONCOLOGY	2200	2200	2200	2200	2200	2200	2200	2200
CM0122-g : GESTATIONAL TROPHOBLAST DISEASES - EMA-CO (complete) ; Day 1 : Act-D - 0.5 mg IV, Etoposide - 100 mg/m2 IV, MTX - 300 mg/m2 IV ; Day 2 : Act-D - 0.5 mg IV, Etoposide - 100 mg/m2 IV, Leucovorin - 15 mg PO/IM q12h 4 doses ; Day 8 : Vincristine - 0.8 mg/m2 IV, Cyclophosphamide - 600 mg/m2 IV ; Repeat cycle every 14 days	MEDICAL ONCOLOGY	6400	6400	6400	6400	6400	6400	6400	6400
CM0122-h : GESTATIONAL TROPHOBLAST DISEASES - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0123 : TESTICULAR CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0123-a : TESTICULAR CANCER - EP ; Days 1-5: Etoposide 100mg/m2, cisplatin 20mg/m2 ; Repeat cycle every 3 weeks for 4 cycles.	MEDICAL ONCOLOGY	5400	5400	5400	5400	5400	5400	5400	5400
CM0123-b : TESTICULAR CANCER - BEP ; Days 1-5: Cisplatin 20mg/m2, etoposide 100mg/m2 ; Days 1, 8, and 15 OR Days 2, 9, or 16: Bleomycin 30 units IV ; Repeat cycle every 3 weeks for 3 cycles.	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0123-c : TESTICULAR CANCER - VIP ; Day 1 (before ifosfamide): Mesna 120mg/m2 IV ; Days 1-5: Etoposide 75mg/m2 IV, mesna 1,200mg/m2 IV, ifosfamide 1,200mg/m2 IV + cisplatin 20mg/m2. ; Repeat cycle every 3 weeks for 4 cycles.	MEDICAL ONCOLOGY	6300	6300	6300	6300	6300	6300	6300	6300
CM0123-d : TESTICULAR CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0124 : PROSTATE CANCERPROSTATE CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0124-a : PROSTATE CANCER - Docetaxel + prednisone ; Day 1: Docetaxel 75mg/m2 IV, prednisone 5mg orally twice daily. ; once every 3 weeks, Repeat for up to 10 cycles if tolerated	MEDICAL ONCOLOGY	3600	3600	3600	3600	3600	3600	3600	3600
CM0124-b : PROSTATE CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0125 : FEBRILE NEUTROPENIA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0125-a : FEBRILE NEUTROPENIA - First-line monotherapy ; Piperacillin-tazobactam 4.5 g ; Cefepime 2 g ; Meropenem 1 g ; Imipenem-cilastatin 500 mg	MEDICAL ONCOLOGY	13500	13500	13500	13500	13500	13500	13500	13500
CM0125-b : FEBRILE NEUTROPENIA - Second-line dual therapy ; Piperacillin-tazobactam 4.5 g IV plus an aminoglycoside ; Meropenem 1 g IV plus an aminoglycoside ; Imipenem-cilastatin 500 mg IV plus an aminoglycoside	MEDICAL ONCOLOGY	19500	19500	19500	19500	19500	19500	19500	19500
CM0125-c : Other Regimen	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0126 : THYROID CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0126-a : THYROID CANCER - sorafenib ; sorafenib 400 mg PO BID	MEDICAL ONCOLOGY	2900	2900	2900	2900	2900	2900	2900	2900
CM0126-b : THYROID CANCER - sunitinib ; sunitinib 50 mg	MEDICAL ONCOLOGY	28500	28500	28500	28500	28500	28500	28500	28500
CM0126-c : THYROID CANCER - pazopanib	MEDICAL ONCOLOGY	9500	9500	9500	9500	9500	9500	9500	9500
CM0126-d : THYROID CANCER - Doxorubicin ; Doxorubicin 60 mg/m2 as monotherapy or in combination with cisplatin 40 mg/m2	MEDICAL ONCOLOGY	4400	4400	4400	4400	4400	4400	4400	4400
CM0126-e : THYROID CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0127 : THYMOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0127-a : THYMOMA - CAP ; Day 1: Cisplatin 50mg/m2 IV, doxorubicin 50mg/m2 IV, cyclophosphamide 500mg/m2 IV. ; Repeat every 21 days for a max of 8 cycles.	MEDICAL ONCOLOGY	4600	4600	4600	4600	4600	4600	4600	4600
CM0127-b : THYMOMA - CAPP ; Day 1: Cyclophosphamide 500mg/m2 IV ; Days 1-3: Cisplatin 30mg/m2 IV ; Days 1-3: Doxorubicin 20mg/m2 ; Days 1-5: Prednisone 100mg. ; Repeat every 3 weeks for 3 cycles.	MEDICAL ONCOLOGY	6800	6800	6800	6800	6800	6800	6800	6800
CM0127-c : THYMOMA - ADOC ; Day 1: Cisplatin 50mg/m2 IV, doxorubicin 40mg/m2 IV ; Day 3: Vincristine 0.6mg/m2 IV ; Day 4: Cyclophosphamide 700mg/m2 IV. ; Repeat every 3 weeks for 5 cycles.	MEDICAL ONCOLOGY	5900	5900	5900	5900	5900	5900	5900	5900
CM0127-d : THYMOMA - PE ; Day 1: Cisplatin 60mg/m2 IV ; Days 1-3: Etoposide 120mg/m2 IV ; Repeat every 3 weeks for a max of 8 cycles.	MEDICAL ONCOLOGY	5100	5100	5100	5100	5100	5100	5100	5100
CM0127-e : THYMOMA - VIP ; Days 1-4: Etoposide 75mg/m2 IV, ifosfamide 1.2g/m2 IV, cisplatin 20mg/m2 IV. ; Repeat every 3 weeks for 4 cycles	MEDICAL ONCOLOGY	7600	7600	7600	7600	7600	7600	7600	7600
CM0127-f : THYMOMA - Carboplatin+paclitaxel ; Day 1: Paclitaxel 225mg/m2 IV, carboplatin AUC = 6 IV ; Repeat every 3 weeks for a max of 6 cycles.	MEDICAL ONCOLOGY	9300	9300	9300	9300	9300	9300	9300	9300
CM0127-g : THYMOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0128 : BRAIN CARCINOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0128-i : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0128-i-a : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma - Combination PCV (lomustine + procarbazine + vincristine) ; Day 1: Lomustine 110mg/m2 orally. ; Days 8-21: Procarbazine 60mg/m2 orally once daily. ; Days 8 and 29: Vincristine 1.4mg/m2 (maximum 2mg) IV. ; Repeat every 6 weeks.	MEDICAL ONCOLOGY	3800	3800	3800	3800	3800	3800	3800	3800
CM0128-i-b : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma - Temozolomide (7 weeks) ; Days 1-49: Temozolomide 75mg/m2 orally. ; Repeat cycle every 11 weeks (7 weeks on/4 weeks off) for 6 cycles.	MEDICAL ONCOLOGY	6500	6500	6500	6500	6500	6500	6500	6500
CM0128-i-c : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma - Temozolomide monthly 5-day course ; Temozolomide monthly 5-day courses at doses of 180 - 200mg/m2/day	MEDICAL ONCOLOGY	2100	2100	2100	2100	2100	2100	2100	2100
CM0128-i-d : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma - Temozolomide (3 weeks) ; Days 1-21: Temozolomide 75mg/m2/day orally. ; Repeat cycle every 28 days.	MEDICAL ONCOLOGY	3400	3400	3400	3400	3400	3400	3400	3400
CM0128-ii : BRAIN CARCINOMA - Systemic Therapy for Anaplastic GliomasSystemic Therapy for Anaplastic Gliomas	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0128-ii-a : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - Temozolomide monthly 5-day course ; Days 1-5: Temozolomide 200mg/m2/day orally. ; Repeat cycle every 4 weeks until disease progression or for up to 24 cycles.	MEDICAL ONCOLOGY	2100	2100	2100	2100	2100	2100	2100	2100
CM0128-ii-b : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - PCV with deferred RT (lomustine + procarbazine + vincristine) ; Day 1: Lomustine 110mg/m2 orally ; Days 8-21: Procarbazine 60mg/m2 orally once daily ; Days 8 and 29: Vincristine 1.4mg/m2 (maximum 2mg) IV. ; Repeat every 6 weeks	MEDICAL ONCOLOGY	3800	3800	3800	3800	3800	3800	3800	3800
CM0128-ii-c : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - Concurrent Temozolomide (with RT) - followed by adjuvant temozolomide ;	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0128-ii-d : Adjuvant Temozolomide	MEDICAL ONCOLOGY	2100	2100	2100	2100	2100	2100	2100	2100
CM0128-ii-e : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - PCV for 1p19q co-deleted (with Radiotherapy) ; Day 1: Lomustine 110mg/m2 orally ; Days 8-21: Procarbazine 60mg/m2 orally once daily ; Days 8 and 29: Vincristine 1.4mg/m2 (maximum 2mg) IV. ; Repeat every 6 weeks. for 6 cycles	MEDICAL ONCOLOGY	3800	3800	3800	3800	3800	3800	3800	3800
CM0128-iii : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0128-iii-a : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma - Concurrent Temozolomide (with RT) - followed by adjuvant temozolomide ; Daily oral temozolomide (75mg/m2/day, 7 days per week from the first to the last day of radiotherapy)	MEDICAL ONCOLOGY	7200	7200	7200	7200	7200	7200	7200	7200
CM0128-iii-b : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma - Adjuvant Temozolomide (preceeded by Concurrent temozolzmide) ; Days 1-5: Temozolomide 150-200mg/m2/day orally for 5 days. ; Repeat cycle every 28 days for 6 cycles.	MEDICAL ONCOLOGY	2100	2100	2100	2100	2100	2100	2100	2100
CM0128-iii-c : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma - Temozolomide (post RT) ; Days 1-5: Temozolomide 150-200mg/m2/day orally for 5 days. ; Repeat cycle every 28 days	MEDICAL ONCOLOGY	2100	2100	2100	2100	2100	2100	2100	2100
CM0128-iii-d : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma - Temozolomide (200mg) with standard RT ; Days 1-5: Temozolomide 200mg/m2, orally	MEDICAL ONCOLOGY	2100	2100	2100	2100	2100	2100	2100	2100
CM0128-iv : BRAIN CARCINOMA - Systemic Therapy for Adult Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumor (PNET)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0128-iv-a : BRAIN CARCINOMA - Systemic Therapy for Adult Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumor (PNET) - Vincristine + cisplatin + lomustine ; Day 1: Lomustine 75mg/m2 orally ; Day 2: Cisplatin 75mg/m2 IV ; Days 2, 8 and 15: Vincristine 1.5mg/m2 IV bolus, max 2mg bolus; ; During Cranio-spinal RT	MEDICAL ONCOLOGY	4400	4400	4400	4400	4400	4400	4400	4400
CM0128-iv-b : BRAIN CARCINOMA - Systemic Therapy for Adult Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumor (PNET) - Vincristine + cisplatin + cyclophosphamide ; Day 1: Cisplatin 75mg/m2 IV ; Days 2, 8 and 15: Vincristine 1.5mg/m2 IV bolus, max 2mg bolus ; Days 22, 23: Cyclophosphamide 1,000mg/m2 IV.	MEDICAL ONCOLOGY	5500	5500	5500	5500	5500	5500	5500	5500
CM0128-v : BRAIN CARCINOMA - Primary CNS LymphomaPrimary CNS Lymphoma	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0128-v-a : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate combined with the following plus radiation therapyHigh dose methotrexate combined with the following plus radiation therapy	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0128-v-a-1 : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose Methotrexate + Cytarabine ; Day 1: MTX 3.5g/m2 ; Days 2-3: Cytarabine 2g/m2 IV twice a day.	MEDICAL ONCOLOGY	6600	6600	6600	6600	6600	6600	6600	6600
CM0128-v-a-2 : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose Methotrexate + leucovorin + Ifosfamide + mesna ; Day 1: MTX 4gm/m2 IV, ; Days 2-5: leucovorin 20-25mg IV (upto 40mg) ; Days 3-5: Ifosfamide 1.5gm/m2 IV + mesna 400mg IV	MEDICAL ONCOLOGY	9500	9500	9500	9500	9500	9500	9500	9500
CM0128-v-b : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate combined with the following plus radiation therapy High dose methotrexate (MTX 2.5-4.0mg/m2) + chemotherapy monoclonal antibody	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0128-v-b-1 : BRAIN CARCINOMA - Primary CNS Lymphoma - Rituximab + MTX + vincristine +procarbazine ; Day 1: Rituximab 500mg/m2 IV ; Day 2: MTX 3.5mg/m2 IV plus vincristine 1.4mg/m2 ; Procarbazine 100mg/m2/day administered for 7 days with odd-numbered cycles	MEDICAL ONCOLOGY	41900	41900	41900	41900	41900	41900	41900	41900
CM0128-v-c : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate (MTX 8.0mg/m2) + chemotherapy +/- monoclonal antibody High dose methotrexate (MTX 8.0mg/m2) + chemotherapy monoclonal antibody	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0128-v-c-1 : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate Induction ; MTX 8g/m2 IV ; Repeat every 2 weeks until complete response achieved or max of 8 cycles reached. ;	MEDICAL ONCOLOGY	7900	7900	7900	7900	7900	7900	7900	7900
CM0128-v-c-2 : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate Consolidation ; MTX 8g/m2 IV administered ; Repeat every 2 weeks for 2 cycles.	MEDICAL ONCOLOGY	7900	7900	7900	7900	7900	7900	7900	7900
CM0128-v-c-3-i : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate Maintanance (Cycles 1-4) ; Day 1: MTX 8g/m2 IV, Rituximab 375mg/m2 IV. ; Repeat every 4 weeks for 4 cycles	MEDICAL ONCOLOGY	32400	32400	32400	32400	32400	32400	32400	32400
CM0128-v-c-3-ii : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate Maintanance (cycles 5-11) ; MTX 8g/m2 IV administered every 4 weeks for 11 cycles. ; Repeat cycle every 4 weeks for 4 cycles	MEDICAL ONCOLOGY	7900	7900	7900	7900	7900	7900	7900	7900
CM0128-v-d : BRAIN CARCINOMA - Primary CNS Lymphoma - Rituximab + Temozolomide regimen	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0128-v-d-1 : BRAIN CARCINOMA - Primary CNS Lymphoma - Rituximab + Temozolomide regimen - Induction ; Day 1: Rituximab 375mg/m2 IV, followed by ; Days 1-5: Temozolomide 150-200mg/m2 orally daily, after rituximab infusion. ; Repeat cycle every 4 weeks for 4 cycles.	MEDICAL ONCOLOGY	26600	26600	26600	26600	26600	26600	26600	26600
CM0128-v-d-2 : BRAIN CARCINOMA - Primary CNS Lymphoma - Rituximab + Temozolomide regimen - MaintananceDays 1-5: Temozolomide 150-200mg/m2 orally daily. ; Repeat cycle every 4 weeks for 8 cycles.	MEDICAL ONCOLOGY	1600	1600	1600	1600	1600	1600	1600	1600
CM0128-v-e : BRAIN CARCINOMA - Meningioma	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0128-v-e-1 : BRAIN CARCINOMA - Meningioma - Interferon-alfaInterferon-alfa ; alpha-IFN 106 units/m2 SC every other day for 4 weeks. ; Repeat cycle every 4 weeks. ;	MEDICAL ONCOLOGY	6000	6000	6000	6000	6000	6000	6000	6000
CM0128-v-e-2 : BRAIN CARCINOMA - Meningioma -Somatostatin analog ; Sandostatin LAR Depot 10-30mg IM ; Repeat every 4 weeks. ;	MEDICAL ONCOLOGY	5400	5400	5400	5400	5400	5400	5400	5400
CM0128-v-e-3 : BRAIN CARCINOMA - Meningioma - Sunitinib ; Days 1-28: Sunitinib 50mg orally daily. ; Repeat cycle every 42 days.	MEDICAL ONCOLOGY	2900	2900	2900	2900	2900	2900	2900	2900
CM0129 : HEAD AND NECK CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0129-i : HEAD AND NECK CANCER - Squamous Cell Cancers	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0129-i-a : HEAD AND NECK CANCER - HIgh Dose Cisplatin ; Cisplatin 100mg/m2 IV + concurrent radiotherapy; Repeat cycle every 3 weeks for 3 cycles	MEDICAL ONCOLOGY	2000	2000	2000	2000	2000	2000	2000	2000
CM0129-i-b : HEAD AND NECK CANCER - Carboplatin + infusional 5-FU ; Days 1-4: 5-FU 600mg/m2/day as continuous IV I, carboplatin 70mg/m2/day IV ; Repeat every 3 weeks for 3 cycles (given concurrently with radiotherapy).	MEDICAL ONCOLOGY	4700	4700	4700	4700	4700	4700	4700	4700
CM0129-i-c : HEAD AND NECK CANCER - 5-FU + hydroxyurea ; Day 1: Hydroxyurea 1,000mg orally every 12 hours (11 doses/cycle), 5-FU 800mg/m2/day ; Repeat every other week for 7 cycles. with Concurrent radiotherapy	MEDICAL ONCOLOGY	2300	2300	2300	2300	2300	2300	2300	2300
CM0129-i-d : HEAD AND NECK CANCER - Cisplatin + paclitaxel ; Day 1: Paclitaxel 30mg/m2 IV (every Monday), ; Day 2: Cisplatin 20mg/m2 IV (every Tuesday). ; Repeat cycle every week for 7 cycles, with Concurrent radiotherapy	MEDICAL ONCOLOGY	3400	3400	3400	3400	3400	3400	3400	3400
CM0129-i-e : HEAD AND NECK CANCER - Cisplatin + infusional 5-FU ; Day 1: Cisplatin 60mg/m2 over ; Days 1-5: 5-FU 800mg/m2/day ; Repeat every other week for 7 cycles. with Concurrent radiotherapy	MEDICAL ONCOLOGY	5300	5300	5300	5300	5300	5300	5300	5300
CM0129-i-f : HEAD AND NECK CANCER - Carboplatin + paclitaxel ; Day 1: Paclitaxel 40-45mg/m2, carboplatin 100mg/m2 ; Repeat cycle every week for 8 cycles, with Concurrent radiotherapy	MEDICAL ONCOLOGY	3500	3500	3500	3500	3500	3500	3500	3500
CM0129-i-g : HEAD AND NECK CANCER - Weekly cisplatin ; Cisplatin 40mg/m2 IV per week	MEDICAL ONCOLOGY	1800	1800	1800	1800	1800	1800	1800	1800
CM0129-i-h : HEAD AND NECK CANCER - Cisplatin (For high risk oropharyngeal carcinoma) ; Days 1, 22, and 43: Cisplatin 100mg/m2 IV + radiotherapy.	MEDICAL ONCOLOGY	5300	5300	5300	5300	5300	5300	5300	5300
CM0129-i-i : HEAD AND NECK CANCER - Docetaxel + cisplatin + 5-FU ; Day 1: Docetaxel 75mg/m2 IV, cisplatin 75mg/m2 IV, ; Days 1-5: 5-FU 750mg/m2/day IV. ; Repeat every 3 weeks for up to 4 cycles.	MEDICAL ONCOLOGY	6700	6700	6700	6700	6700	6700	6700	6700
CM0129-i-j : HEAD AND NECK CANCER - Paclitaxel + cisplatin+ infusional 5-FU ; Day 1: Paclitaxel 175mg/m2 ; Day 2: Cisplatin 100mg/m2 ; Day 2-6: 5-FU 500mg/m2/day IV ; Repeat every 3 weeks for 3 cycles.	MEDICAL ONCOLOGY	7900	7900	7900	7900	7900	7900	7900	7900
CM0129-ii : HEAD AND NECK CANCER - Nasopharynx Cancer	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0129-ii-a : Nasopharynx Cancer - Concurrent Cisplatin followed by concurrent Cisplatin +5FUC ;	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0129-ii-a-1 : Nasopharynx Cancer - Concurrent Cisplatin (followed by concurrent Cisplatin +5FU) ; Day 1: Cisplatin 100mg/m2 IV; plus radiotherapy. ; Repeat cycle every 3 weeks for 3 cycles; followed by concurrent Cisplatin +5FU	MEDICAL ONCOLOGY	2000	2000	2000	2000	2000	2000	2000	2000
CM0129-ii-a-2 : Nasopharynx Cancer - concurrent Cisplatin +5FU - Preceeded by (Concurrent Cisplatin 3 cycles) ; Days 1-4: Cisplatin 80mg/m2/day, 5-FU 1,000mg/m2/day IV ; Repeat cycle every 4 weeks for 3 cycles	MEDICAL ONCOLOGY	6700	6700	6700	6700	6700	6700	6700	6700
CM0129-ii-b : Nasopharynx Cancer - Concurrent Carboplatin followed by concurrent Carboplatin +5FU	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0129-ii-b-1 : Nasopharynx Cancer - Concurrent Carboplatin - (followed by concurrent Carboplatin +5FU) ; Day 1: Carboplatin AUC 6mg/min/mL IV. ; Repeat cycle every 3 weeks for 3 cycles;	MEDICAL ONCOLOGY	4300	4300	4300	4300	4300	4300	4300	4300
CM0129-ii-b-2 : Nasopharynx Cancer - concurrent Carboplatin +5FU - Preceeded by (Concurrent Carboplatin ) ; Day 1: Carboplatin AUC 5mg/min/mL IV ; Days 1-4: 5-FU 1,000mg/m2/day IV ; Repeat cycle every 3 weeks for 3 cycles.	MEDICAL ONCOLOGY	13500	13500	13500	13500	13500	13500	13500	13500
CM0129-ii-c : Nasopharynx Cancer - Concurrent Cisplatin ; Cisplatin 40mg/m2 ; Repeat weekly for 7 cycles	MEDICAL ONCOLOGY	1800	1800	1800	1800	1800	1800	1800	1800
CM0129-ii-d : Nasopharynx Cancer - Docetaxel + cisplatin + 5-FU followed by Cisplatin ;	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0129-ii-d-1 : Nasopharynx Cancer - Docetaxel + cisplatin + 5-FU - followed by Cisplatin after 3 cycles ; Day 1: Docetaxel 70mg/m2 IV, cisplatin 75mg/m2 IV ; Days 1-4: 5-FU 1,000mg/m2/day IV ; Repeat every week for 3 cycles	MEDICAL ONCOLOGY	6200	6200	6200	6200	6200	6200	6200	6200
CM0129-ii-d-2 : Nasopharynx Cancer - Cisplatin - weekly - Preceded by 3 cycles of Docetaxel + 5-FU ; Day 1: Cisplatin 100mg/m2; ; Repeat every 3 weeks, Till radiation	MEDICAL ONCOLOGY	2800	2800	2800	2800	2800	2800	2800	2800
CM0129-ii-e : Nasopharynx Cancer - Docetaxel + cisplatin	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0129-ii-e-1 : Nasopharynx Cancer - Docetaxel + cisplatin - followed by Cisplatin after 2 cycles ; Day 1: Docetaxel 75mg/m2 IV + cisplatin 75mg/m2 IV ; Repeat every 3 weeks for two cycles	MEDICAL ONCOLOGY	3900	3900	3900	3900	3900	3900	3900	3900
CM0129-ii-e-2 : Nasopharynx Cancer - Cisplatin - weekly - Preceded by 2 cycles of Docetaxel + cisplatin ; Cisplatin 40mg/m2 IV ; weekly concurrent with radiotherapy.	MEDICAL ONCOLOGY	2300	2300	2300	2300	2300	2300	2300	2300
CM0129-ii-f : Nasopharynx Cancer - Cisplatin + 5-FU ; Day 1: Cisplatin 100mg/m2/day IV. ; Days 1-4: 5-FU 1,000mg/m2/day continuous IV infusion for 4 days. ; Repeat cycle every 3 weeks for a minimum of 6 cycles	MEDICAL ONCOLOGY	5100	5100	5100	5100	5100	5100	5100	5100
CM0129-iii : HEAD AND NECK CANCER (or) Nasopharynx Cancer - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0130 : RENAL CELL CARCINOMARENAL CELL CARCINOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0130-a : Pazopanib	MEDICAL ONCOLOGY	19000	19000	19000	19000	19000	19000	19000	19000
CM0130-b : Sunitinib	MEDICAL ONCOLOGY	29000	29000	29000	29000	29000	29000	29000	29000
CM0130-c : Sorafenib	MEDICAL ONCOLOGY	5800	5800	5800	5800	5800	5800	5800	5800
CM0130-d : Other Regimen	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0131 : UNKNOWN PRIMARYUNKNOWN PRIMARY	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0131-i : UNKNOWN PRIMARY - Adenocarcinoma	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0131-i-a : UNKNOWN PRIMARY - Adenocarcinoma - Paclitaxel + carboplatin + etoposide ; Day 1: Paclitaxel 200 mg/m 2 IV, carboplatin AUC 6 ; Days 1-10: etoposide 50 mg PO alternating with 100 mg daily ; Repeat every 21days for 2-3 cycles; restage, can be treated upto 8 cycles	MEDICAL ONCOLOGY	8000	8000	8000	8000	8000	8000	8000	8000
CM0131-i-b : UNKNOWN PRIMARY - Adenocarcinoma - Paclitaxel + carboplatin ; Day 1: Paclitaxel 200 mg/m 2, carboplatin AUC 6 ; Repeat cycle every 3 weeks, Maximum 8 cycles	MEDICAL ONCOLOGY	7200	7200	7200	7200	7200	7200	7200	7200
CM0131-i-c : UNKNOWN PRIMARY - Adenocarcinoma - Docetaxel + carboplatin ; Day 1: Docetaxel 65mg/m2 IV, carboplatin AUC 6 ; Repeat cycle every 3 weeks, Maximum 8 cycles.	MEDICAL ONCOLOGY	3800	3800	3800	3800	3800	3800	3800	3800
CM0131-i-d : UNKNOWN PRIMARY - Adenocarcinoma - Gemcitabine + cisplatin ; Day 1: Cisplatin 100mg/m2 IV ; Day 1 and 8: Gemcitabine 1250mg/m2 IV. ; Repeat cycle every 3 weeks for 4 cycles.	MEDICAL ONCOLOGY	5300	5300	5300	5300	5300	5300	5300	5300
CM0131-i-e : UNKNOWN PRIMARY - Adenocarcinoma - Gemcitabine + docetaxel ; Day 1 and 8: Gemcitabine 1000mg/m2 IV over 30 minutes ; Day 8: Docetaxel 75mg/m2 IV ; Repeat cycle every 3 weeks for a maximum of 6 cycles	MEDICAL ONCOLOGY	5800	5800	5800	5800	5800	5800	5800	5800
CM0131-i-f : UNKNOWN PRIMARY - Adenocarcinoma - Gemcitabine + irinotecan ; Days 1 and 8: Irinotecan 100mg/m2 IV, gemcitabine 1000mg/m2 IV. ; Repeat cycle every 3 weeks for 6 cycles.restage every 2-3 cycles	MEDICAL ONCOLOGY	5600	5600	5600	5600	5600	5600	5600	5600
CM0131-ii : UNKNOWN PRIMARY - Squamous cell carcinoma	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0131-ii-a : UNKNOWN PRIMARY - Squamous cell carcinoma - Paclitaxel + cisplatin + 5-FU ; Paclitaxel 175 mg/m 2 IV, ; Day 2: cisplatin 100 mg/m 2 IV, ; Day 5-FU (5-fluorouracil) 500 mg/m 2/day IV ; Repeat every 21d	MEDICAL ONCOLOGY	6200	6200	6200	6200	6200	6200	6200	6200
CM0131-ii-b : UNKNOWN PRIMARY - Squamous cell carcinoma - Docetaxel + cisplatin + 5-FU ; Day 1: Docetaxel 75mg/m2 IV, cisplatin 75mg/m2 IV. ; Days 1-5: 5-FU 750mg/m2/day IV ; Repeat cycle every 3 weeks for 3 cycles.	MEDICAL ONCOLOGY	6800	6800	6800	6800	6800	6800	6800	6800
CM0131-iii : UNKNOWN PRIMARY - Neuroendocrine tumors	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0131-iii-b : UNKNOWN PRIMARY - Neuroendocrine tumors - Etoposide + cisplatin ; Days 1-3: Etoposide 100 mg/m 2 ; Days 2-3: cisplatin 45 mg/m 2 IV ; Repeat every 28 days	MEDICAL ONCOLOGY	5000	5000	5000	5000	5000	5000	5000	5000
CM0131-iv : UNKNOWN PRIMARY - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0132 : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMACA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0132-a : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - Gemcitabine + cisplatin ; Days 1 and 8: Cisplatin 25mg/m2 IV, gemcitabine 1,000mg/m2 IV ; Repeat every 21 days for 4 cycles, re-evaluate and continue an additional 4 cycles if warranted	MEDICAL ONCOLOGY	3700	3700	3700	3700	3700	3700	3700	3700
CM0132-b : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - 5-FU ; 5 - FU IV	MEDICAL ONCOLOGY	4100	4100	4100	4100	4100	4100	4100	4100
CM0132-c : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - Capecitabine ; Capecitabine oral ; Repeat every 21 days	MEDICAL ONCOLOGY	3600	3600	3600	3600	3600	3600	3600	3600
CM0132-d : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0133 : PANCREAS CARCINOMAPANCREAS CARCINOMA -	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0133-i : PANCREAS CARCINOMA - Patients with resectable pancreatic cancer - Locally Advanced ;	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0133-i-a : PANCREAS CARCINOMA - Patients with resectable pancreatic cancer - Locally Advanced Gemcitabine ; Days 1, 8, and 15: Gemcitabine 1,000mg/m2 IV ; Repeat every 4 weeks for six cycles	MEDICAL ONCOLOGY	6600	6600	6600	6600	6600	6600	6600	6600
CM0133-ii : PANCREAS CARCINOMA - Adjuvant chemotherapy and chemoradiation	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0133-ii-a : PANCREAS CARCINOMA - Adjuvant chemotherapy and chemoradiation - 5-FU + Leucovorin ; Days 1-5: Leucovorin 20mg/m2 IV, 5-FU 425mg/m2 IV ; Repeat cycle every 4 weeks	MEDICAL ONCOLOGY	5000	5000	5000	5000	5000	5000	5000	5000
CM0133-ii-b : PANCREAS CARCINOMA - Adjuvant chemotherapy and chemoradiation - Gemcitabine & 5FU ; Prior to chemoradiation: ; Days 1, 8 and 15: Gemcitabine 1,000mg/m2 IV; initiate 1-2 weeks prior to chemoradiation (50.4Gy + 5-FU 250mg/m2/day). ; After chemoradiation: ; Days 1, 8 and 15: Gemcitabine 1,000mg/m2 IV; initiate 3-5 weeks following chemoradiation. ; Repeat cycle every 4 weeks for 3 months.	MEDICAL ONCOLOGY	6700	6700	6700	6700	6700	6700	6700	6700
CM0133-ii-c : PANCREAS CARCINOMA - Adjuvant chemotherapy and chemoradiation - Continuous infusion 5-FU (with Radiation) ; Prior to chemoradiation: ; Days 1-21: 5-FU 250mg/m2/day continuous IV infusion; initiate 1-2 weeks prior to chemoradiation (50.4Gy + 5-FU 250mg/m2/day). ; After chemoradiation: ; Days 1-28: 5-FU 250mg/m2/day continuous IV infusion; initiate 3-5 weeks following chemoradiation. ; Repeat cycle every 6 weeks for 3 months.	MEDICAL ONCOLOGY	20700	20700	20700	20700	20700	20700	20700	20700
CM0133-iii : PANCREAS CARCINOMA - Neoadjuvant therapy - Neoadjuvant therapy	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0133-iii-a : PANCREAS CARCINOMA - Neoadjuvant therapy - CapecitabineCapecitabine ; Capecitabine ; Repeat cycle every 3 weeks for up to 52 weeks.	MEDICAL ONCOLOGY	3600	3600	3600	3600	3600	3600	3600	3600
CM0133-iv : PANCREAS CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0134 : PERI AMPULLARY CARCINOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0134-a : PERI AMPULLARY CARCINOMA - 5-FU ; Fluorouracil 425 mg/m2 administered on days 1 to 5 and 29-33	MEDICAL ONCOLOGY	5300	5300	5300	5300	5300	5300	5300	5300
CM0134-b : PERI AMPULLARY CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0135 : NEURO ENDOCRINE CARCINOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0135-a : NEURO ENDOCRINE CARCINOMA - All NECs are covered under Organ Cancers. If uncovered - Unlisted only.	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0135-b : NEURO ENDOCRINE CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0136 : SARCOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0136-i : SARCOMA - Gastrointestinal Stromal Tumor - GIST	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0136-i-a : SARCOMA - Gastrointestinal Stromal Tumor - GIST - Imatinib ; Imatinib 400mg orally once daily to twice daily	MEDICAL ONCOLOGY	3000	3000	3000	3000	3000	3000	3000	3000
CM0136-ii : SARCOMA - SOFT TISSUE SARCOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0136-ii-a : SARCOMA - SOFT TISSUE SARCOMA - Doxorubicin + dacarbazine (AD) ; Days 1-4: Doxorubicin 60mg/m2 + dacarbazine 750mg/m2 ; Repeat cycle every 3 weeks	MEDICAL ONCOLOGY	11500	11500	11500	11500	11500	11500	11500	11500
CM0136-ii-b : SARCOMA - SOFT TISSUE SARCOMA - Doxorubicin + ifosfamide + mesna ; Days 1 and 2: Doxorubicin 30mg/m2/day IV, ifosfamide 3,750mg/m2/day IV, mesna 750mg/m2 IV ; Repeat cycle every 3 weeks	MEDICAL ONCOLOGY	9200	9200	9200	9200	9200	9200	9200	9200
CM0136-ii-c : SARCOMA - SOFT TISSUE SARCOMA - Mesna + doxorubicin + ifosfamide + dacarbazine (MAID) ; Days 1-3: Doxorubicin 20mg/m2/day, ifosfamide 2,500mg/m2/day, dacarbazine 300mg/m2/day IV ; Days 1-4: Mesna 2,500mg/m2/day IV for 84 to 96 hours. ; Repeat cycle every 3 weeks.	MEDICAL ONCOLOGY	10700	10700	10700	10700	10700	10700	10700	10700
CM0136-ii-d : SARCOMA - SOFT TISSUE SARCOMA - Ifosfamide + epirubicin + mesna ; Days 1 and 2: Epirubicin 60mg/m2/day IV ; Days 1-5: Ifosfamide 1.8g/m2/day IV + mesna. ; Repeat cycle every 3 weeks for 5 cycles.	MEDICAL ONCOLOGY	12800	12800	12800	12800	12800	12800	12800	12800
CM0136-ii-e : SARCOMA - SOFT TISSUE SARCOMA - Gemcitabine + docetaxel ; Days 1 and 8: Gemcitabine 900mg/m2 IV ; Day 8: Docetaxel 100mg/m2 IV. ; Repeat cycle every 3 weeks	MEDICAL ONCOLOGY	5100	5100	5100	5100	5100	5100	5100	5100
CM0136-ii-f : SARCOMA - SOFT TISSUE SARCOMA - Gemcitabine + vinorelbine ; Days 1 and 8: Vinorelbine 25mg/m2 IV, gemcitabine 800mg/m2 IV ; Repeat cycle every 3 weeks	MEDICAL ONCOLOGY	14700	14700	14700	14700	14700	14700	14700	14700
CM0136-ii-g : SARCOMA - SOFT TISSUE SARCOMA - Gemcitabine + dacarbazine ; Day 1: Gemcitabine 1,800mg/m2 IV + dacarbazine 500mg/m2 IV. ; Repeat cycle ever 2 weeks for a total of 12 cycles;	MEDICAL ONCOLOGY	3300	3300	3300	3300	3300	3300	3300	3300
CM0136-ii-h : SARCOMA - SOFT TISSUE SARCOMA - Doxorubicin ; Doxorubicin 60-75mg/m2 IV ; once every 3 weeks	MEDICAL ONCOLOGY	2900	2900	2900	2900	2900	2900	2900	2900
CM0136-ii-i : SARCOMA - SOFT TISSUE SARCOMA - Ifosfamide ; Days 1-3: Ifosfamide 2,000-3,000mg/m2/day IV for 3 to 4 days + mesna ; Repeat every 3 weeks.	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0136-ii-j : SARCOMA - SOFT TISSUE SARCOMA - Ifosfamide ; Day 1: Ifosfamide 5,000mg/m2 + mesna 5,000mg/m2 IV ; Day 2: mesna 400-600mg/m2 IV ; Ifosfamide, mesna ; Repeat every 3 weeks	MEDICAL ONCOLOGY	1900	1900	1900	1900	1900	1900	1900	1900
CM0136-ii-k : SARCOMA - SOFT TISSUE SARCOMA - Epirubicin ; Epirubicin 160mg/m2 IV ; Repeat every 3 weeks	MEDICAL ONCOLOGY	5900	5900	5900	5900	5900	5900	5900	5900
CM0136-ii-l : SARCOMA - SOFT TISSUE SARCOMA - Gemcitabine ; Days 1 and 8: Gemcitabine 1,200mg/m2 IV ; Repeat cycle every 3 weeks.	MEDICAL ONCOLOGY	3600	3600	3600	3600	3600	3600	3600	3600
CM0136-ii-m : SARCOMA - SOFT TISSUE SARCOMA - Dacarbazine (i) ; Dacarbazine 250mg/m2/day IV for 5 days ; Repeat every 3 weeks.	MEDICAL ONCOLOGY	6200	6200	6200	6200	6200	6200	6200	6200
CM0136-ii-n : SARCOMA - SOFT TISSUE SARCOMA - Dacarbazine (ii) ; Dacarbazine 800-1,000mg/m2 IV ; Repeat every 3 weeks.	MEDICAL ONCOLOGY	2400	2400	2400	2400	2400	2400	2400	2400
CM0136-ii-o : SARCOMA - SOFT TISSUE SARCOMA - Liposomal doxorubicin ; Liposomal doxorubicin 30-50mg/m2 IV ; Repeat every 4 weeks.	MEDICAL ONCOLOGY	7900	7900	7900	7900	7900	7900	7900	7900
CM0136-ii-p : SARCOMA - SOFT TISSUE SARCOMA - Temozolomide ; Temozolomide 200mg/m2 orally twice daily for 5 days, followed by 9 doses of 90mg/m2 orally ; Repeat every 4 weeks	MEDICAL ONCOLOGY	4200	4200	4200	4200	4200	4200	4200	4200
CM0136-iii : SARCOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0137 : PRIMITIVE NEURO ECTODERMAL TUMOR	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0137-a : PRIMITIVE NEURO ECTODERMAL TUMOR - Weekly vincristine ; vincristine 1.5mg/m2 IV, max 2mg ; for 5 to 6 weeks	MEDICAL ONCOLOGY	1700	1700	1700	1700	1700	1700	1700	1700
CM0137-b : PRIMITIVE NEURO ECTODERMAL TUMOR - Vincristine + cisplatin + lomustine ; During craniospinal radiotherapy (RT) ; Day 1: Lomustine 75mg/m2 orally ; Day 2: Cisplatin 75mg/m2 IV ; Days 2, 8 and 15: Vincristine 1.5mg/m2 IV bolus, max 2mg bolus; up to max 8 doses	MEDICAL ONCOLOGY	4400	4400	4400	4400	4400	4400	4400	4400
CM0137-c : PRIMITIVE NEURO ECTODERMAL TUMOR - Vincristine + cisplatin + cyclophosphamide ; Day 1: Cisplatin 75mg/m2 IV ; Days 2, 8 and 15: Vincristine 1.5mg/m2 IV, max 2mg ; Days 22, 23: Cyclophosphamide 1,000mg/m2 IV	MEDICAL ONCOLOGY	7600	7600	7600	7600	7600	7600	7600	7600
CM0137-d : PRIMITIVE NEURO ECTODERMAL TUMOR - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0137-vi : Other Regimen	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0138 : MELANOMA - No primary regimens only RT. For advanced unresectable and metastatic disease - Pallitive Chemotherapy	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0139 : ANAL CANAL CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0139-a : ANAL CANAL CANCER - 5-FU + Mitomycin ; Days 1-4 and 29-32: 5-FU 1,000mg/m2/day IV ; Days 1 and 29: Mitomycin 10mg/m2 IV bolus (maximum 20mg per course), with Concurrent radiotherapy	MEDICAL ONCOLOGY	11400	11400	11400	11400	11400	11400	11400	11400
CM0139-b : ANAL CANAL CANCER - Capecitabine + Mitomycin (i) ; Days 1-5: Capecitabine 825mg/m2 orally twice daily weekly for 6 weeks, ; Days 1 and 29: Mitomycin 10mg/m2 IV bolus, with Concurrent radiotherapy.	MEDICAL ONCOLOGY	8100	8100	8100	8100	8100	8100	8100	8100
CM0139-c : ANAL CANAL CANCER - Capecitabine + Mitomycin (ii) ; Days 1-5: Capecitabine 825mg/m2 orally twice daily weekly for 6 weeks, ; Day 1: Mitomycin 12mg/m2 IV bolus, with Concurrent radiotherapy	MEDICAL ONCOLOGY	6800	6800	6800	6800	6800	6800	6800	6800
CM0139-d : ANAL CANAL CANCER - Cisplatin + 5-FU ; Days 1-5: 5-FU 1,000mg/m2/day IV ; Day 2: Cisplatin 100mg/m2 IV ; Repeat cycle every 4 weeks, with Concurrent radiotherapy	MEDICAL ONCOLOGY	6700	6700	6700	6700	6700	6700	6700	6700
CM0139-e : ANAL CANAL CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0952 : SURGERY/CHEMOTHERAPY/RADIOTHERAPY FOR ALL LEUKEMIAS	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0952A : All Leukemia ( Chemotheraphy)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0952A-I : Chronic Myeloid Leukemia (CML)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0952A-I-i-a : Imatinib	MEDICAL ONCOLOGY	1525	1525	1525	1525	1525	1525	1525	1525
CM0952A-I-i-b : Nilotinib	MEDICAL ONCOLOGY	17800	17800	17800	17800	17800	17800	17800	17800
CM0952A-I-ii : Blast phase-Lymphoid ALL Type Induction + TKI	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0952A-I-ii-a : Induction	MEDICAL ONCOLOGY	12840	12840	12840	12840	12840	12840	12840	12840
CM0952A-I-ii-b : Imatinib	MEDICAL ONCOLOGY	1525	1525	1525	1525	1525	1525	1525	1525
CM0952A-I-ii-c : Nilotinib	MEDICAL ONCOLOGY	17800	17800	17800	17800	17800	17800	17800	17800
CM0952A-I-iii : Blast phase-myeloid AML Type Induction + TKI	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0952A-I-iii-a : Daunorubicin (90mg/m2)+ Cytarabine	MEDICAL ONCOLOGY	12320	12320	12320	12320	12320	12320	12320	12320
CM0952A-I-iii-b : Daunorubicin + Cytarabine + Cladribine	MEDICAL ONCOLOGY	10365	10365	10365	10365	10365	10365	10365	10365
CM0952A-I-iii-c : Daunorubicin + Cytarabine (High Dose)	MEDICAL ONCOLOGY	16725	16725	16725	16725	16725	16725	16725	16725
CM0952A-I-iii-d : Daunorubicin (90mg) + Cytarabine	MEDICAL ONCOLOGY	12320	12320	12320	12320	12320	12320	12320	12320
CM0952A-I-iii-e : Idarubicin + Cytarabine (High Dose)	MEDICAL ONCOLOGY	29600	29600	29600	29600	29600	29600	29600	29600
CM0952A-I-iii-f : Idarubicin + Cytarabine	MEDICAL ONCOLOGY	23240	23240	23240	23240	23240	23240	23240	23240
CM0952A-I-iii-g : mitoxantrone + Cytarabine	MEDICAL ONCOLOGY	10820	10820	10820	10820	10820	10820	10820	10820
CM0952A-I-iii-h : Imatinib	MEDICAL ONCOLOGY	1525	1525	1525	1525	1525	1525	1525	1525
CM0952A-I-iii-i : Nilotinib	MEDICAL ONCOLOGY	17800	17800	17800	17800	17800	17800	17800	17800
CM0952A-I-iii-ii : Other Regimen	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0952A-I-iii-iii : Other Regimen	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0952A-II : Acute Myeloid Leukemia (AML)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0952A-II-a : Daunorubicin + Cytarabine 1	MEDICAL ONCOLOGY	12320	12320	12320	12320	12320	12320	12320	12320
CM0952A-II-b : Idarubicin + Cytarabine	MEDICAL ONCOLOGY	23240	23240	23240	23240	23240	23240	23240	23240
CM0952A-II-c : Daunorubicin + Cytarabine 2	MEDICAL ONCOLOGY	10365	10365	10365	10365	10365	10365	10365	10365
CM0952A-II-d : Daunorubicin + Cytarabine (High Dose)	MEDICAL ONCOLOGY	16725	16725	16725	16725	16725	16725	16725	16725
CM0952A-II-e : Idarubicin + Cytarabine (High Dose)	MEDICAL ONCOLOGY	29600	29600	29600	29600	29600	29600	29600	29600
CM0952A-II-f : Daunorubicin (90mg) + Cytarabine	MEDICAL ONCOLOGY	12320	12320	12320	12320	12320	12320	12320	12320
CM0952A-II-g : idarubicin + Cytarabine	MEDICAL ONCOLOGY	23240	23240	23240	23240	23240	23240	23240	23240
CM0952A-II-h : mitoxantrone + Cytarabine	MEDICAL ONCOLOGY	10280	10280	10280	10280	10280	10280	10280	10280
CM0952A-II-i : Cytarabine	MEDICAL ONCOLOGY	6800	6800	6800	6800	6800	6800	6800	6800
CM0952A-II-j : Decitabine	MEDICAL ONCOLOGY	25000	25000	25000	25000	25000	25000	25000	25000
CM0952A-II-k : azacytidine	MEDICAL ONCOLOGY	77500	77500	77500	77500	77500	77500	77500	77500
CM0952A-II-l : Hydroxyurea	MEDICAL ONCOLOGY	1600	1600	1600	1600	1600	1600	1600	1600
CM0952A-II-m : Cytarabine - High Dose	MEDICAL ONCOLOGY	9720	9720	9720	9720	9720	9720	9720	9720
CM0952A-II-n : Cladribine + Cytarabine + Idarubicin + Gcsf	MEDICAL ONCOLOGY	85150	85150	85150	85150	85150	85150	85150	85150
CM0952A-II-o : Cladribine + Cytarabine + Mitoxantrone + Gcsf	MEDICAL ONCOLOGY	40690	40690	40690	40690	40690	40690	40690	40690
CM0952A-II-p : Fludarabine + Cytarabine + Idarubicin + Gcsf	MEDICAL ONCOLOGY	66710	66710	66710	66710	66710	66710	66710	66710
CM0952A-II-q : Etoposide +Cytarabine+Mitoxantrone	MEDICAL ONCOLOGY	13260	13260	13260	13260	13260	13260	13260	13260
CM0952A-II-r : Cytarabine SC	MEDICAL ONCOLOGY	2800	2800	2800	2800	2800	2800	2800	2800
CM0952A-II-s : azacytidine	MEDICAL ONCOLOGY	77500	77500	77500	77500	77500	77500	77500	77500
CM0952A-II-t : Decitabine	MEDICAL ONCOLOGY	25500	25500	25500	25500	25500	25500	25500	25500
CM0952A-II-u : Other Regimen	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0952A-III : Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0952A-III-a-i : Rituximab + chlorambucil Cycle 1	MEDICAL ONCOLOGY	1084	1084	1084	1084	1084	1084	1084	1084
CM0952A-III-a-ii : Rituximab + chlorambucil Cycle 3	MEDICAL ONCOLOGY	25584	25584	25584	25584	25584	25584	25584	25584
CM0952A-III-a-iii : Rituximab + chlorambucil Cycle 4-8	MEDICAL ONCOLOGY	32984	32984	32984	32984	32984	32984	32984	32984
CM0952A-III-a-iv : Maintanance - Rituximab	MEDICAL ONCOLOGY	25500	25500	25500	25500	25500	25500	25500	25500
CM0952A-III-b : Rituximab Day 1, 8, 15, and 22:	MEDICAL ONCOLOGY	100500	100500	100500	100500	100500	100500	100500	100500
CM0952A-III-c : Chlorambucil	MEDICAL ONCOLOGY	2344	2344	2344	2344	2344	2344	2344	2344
CM0952A-III-d-i : Bendamustine + Rituximab (Cycle -1)	MEDICAL ONCOLOGY	36500	36500	36500	36500	36500	36500	36500	36500
CM0952A-III-d-ii : Bendamustine + Rituximab (Cycles 2-6)	MEDICAL ONCOLOGY	37900	37900	37900	37900	37900	37900	37900	37900
CM0952A-III-d-iii : Bendamustine (70mg) (Cycle -1)	MEDICAL ONCOLOGY	12500	12500	12500	12500	12500	12500	12500	12500
CM0952A-III-d-iv : Bendamustine (90 mg) (Cycles 2-6)	MEDICAL ONCOLOGY	6500	6500	6500	6500	6500	6500	6500	6500
CM0952A-III-e : Fludarabine + cyclophosphamide + rituximab (FCR)	MEDICAL ONCOLOGY	31898	31898	31898	31898	31898	31898	31898	31898
CM0952A-III-f : Fludarabine + rituximab (FR)	MEDICAL ONCOLOGY	67930	67930	67930	67930	67930	67930	67930	67930
CM0952A-III-g : Alemtuzumab + rituximab	MEDICAL ONCOLOGY	108950	108950	108950	108950	108950	108950	108950	108950
CM0952A-III-h : Alemtuzumab without rituximab	MEDICAL ONCOLOGY	11450	11450	11450	11450	11450	11450	11450	11450
CM0952A-III-i : High-dose methylprednisolone + rituximab	MEDICAL ONCOLOGY	103955	103955	103955	103955	103955	103955	103955	103955
CM0952A-III-j : High-dose methylprednisolone	MEDICAL ONCOLOGY	6455	6455	6455	6455	6455	6455	6455	6455
CM0952A-III-k : Other Regimen	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0952A-IV : Acute Lymphoblastic Leukemia (ALL)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0952A-IV-i : Ph(+) AYA (Age 15-39 years)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0952A-IV-i-a-1 : Childrens Oncology Group (COG) AALL-0031 INDUCTION PHASE	MEDICAL ONCOLOGY	13340	13340	13340	13340	13340	13340	13340	13340
CM0952A-IV-i-a-2 : Childrens Oncology Group (COG) AALL-0031 CONSOLIDATION PHASE - BLOCK 1	MEDICAL ONCOLOGY	17095	17095	17095	17095	17095	17095	17095	17095
CM0952A-IV-i-a-3 : Childrens Oncology Group (COG) AALL-0031 CONSOLIDATION PHASE - BLOCK 2	MEDICAL ONCOLOGY	19175	19175	19175	19175	19175	19175	19175	19175
CM0952A-IV-i-a-4 : Childrens Oncology Group (COG) AALL-0031 REINDUCTION	MEDICAL ONCOLOGY	25291	25291	25291	25291	25291	25291	25291	25291
CM0952A-IV-i-a-5 : Childrens Oncology Group (COG) AALL-0031 INTENSIFICATION	MEDICAL ONCOLOGY	41425	41425	41425	41425	41425	41425	41425	41425
CM0952A-IV-i-a-6 : Childrens Oncology Group (COG) AALL-0031 MAINTENANCE Cycles 1-4 (8 weeks)	MEDICAL ONCOLOGY	35621	35621	35621	35621	35621	35621	35621	35621
CM0952A-IV-i-a-7 : Childrens Oncology Group (COG) AALL-0031 MAINTENANCE Cycles 5-12 (8 weeks)	MEDICAL ONCOLOGY	12836	12836	12836	12836	12836	12836	12836	12836
CM0952A-IV-i-b-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3)	MEDICAL ONCOLOGY	59429	59429	59429	59429	59429	59429	59429	59429
CM0952A-IV-i-b-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4)	MEDICAL ONCOLOGY	62380	62380	62380	62380	62380	62380	62380	62380
CM0952A-IV-i-b-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7)	MEDICAL ONCOLOGY	11469	11469	11469	11469	11469	11469	11469	11469
CM0952A-IV-i-b-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8)	MEDICAL ONCOLOGY	13420	13420	13420	13420	13420	13420	13420	13420
CM0952A-IV-i-b-5 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction II	MEDICAL ONCOLOGY	15133	15133	15133	15133	15133	15133	15133	15133
CM0952A-IV-i-b-6 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction III	MEDICAL ONCOLOGY	5535	5535	5535	5535	5535	5535	5535	5535
CM0952A-IV-i-b-7 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Maintenance	MEDICAL ONCOLOGY	9923	9923	9923	9923	9923	9923	9923	9923
CM0952A-IV-i-c-1 : Multiagent Chemotherapy + TKIs INDUCTION PHASE	MEDICAL ONCOLOGY	15133	15133	15133	15133	15133	15133	15133	15133
CM0952A-IV-i-c-2 : Multiagent Chemotherapy + TKIs CONSOLIDATION I	MEDICAL ONCOLOGY	8460	8460	8460	8460	8460	8460	8460	8460
CM0952A-IV-i-c-3 : Multiagent Chemotherapy + TKIs CONSOLIDATION II	MEDICAL ONCOLOGY	3700	3700	3700	3700	3700	3700	3700	3700
CM0952A-IV-i-c-4 : Multiagent Chemotherapy + TKIs MAINTENANCE	MEDICAL ONCOLOGY	3410	3410	3410	3410	3410	3410	3410	3410
CM0952A-IV-i-c-5 : Imatinib	MEDICAL ONCOLOGY	1525	1525	1525	1525	1525	1525	1525	1525
CM0952A-IV-i-c-6 : Nilotinib	MEDICAL ONCOLOGY	17800	17800	17800	17800	17800	17800	17800	17800
CM0952A-IV-i-d : Other Regimen	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0952A-IV-ii : Ph(+) AYA (Age > 40 years)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0952A-IV-ii-a-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3)	MEDICAL ONCOLOGY	59429	59429	59429	59429	59429	59429	59429	59429
CM0952A-IV-ii-a-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4)	MEDICAL ONCOLOGY	62380	62380	62380	62380	62380	62380	62380	62380
CM0952A-IV-ii-a-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7)	MEDICAL ONCOLOGY	11469	11469	11469	11469	11469	11469	11469	11469
CM0952A-IV-ii-a-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8)	MEDICAL ONCOLOGY	13420	13420	13420	13420	13420	13420	13420	13420
CM0952A-IV-ii-a-5 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction II	MEDICAL ONCOLOGY	15133	15133	15133	15133	15133	15133	15133	15133
CM0952A-IV-ii-a-6 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction III	MEDICAL ONCOLOGY	5535	5535	5535	5535	5535	5535	5535	5535
CM0952A-IV-ii-a-7 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Maintenance	MEDICAL ONCOLOGY	9923	9923	9923	9923	9923	9923	9923	9923
CM0952A-IV-ii-b-1 : Multiagent Chemotherapy + TKIs INDUCTION PHASE	MEDICAL ONCOLOGY	15573	15573	15573	15573	15573	15573	15573	15573
CM0952A-IV-ii-b-2 : Multiagent Chemotherapy + TKIs CONSOLIDATION I	MEDICAL ONCOLOGY	12110	12110	12110	12110	12110	12110	12110	12110
CM0952A-IV-ii-b-3 : Multiagent Chemotherapy + TKIs CONSOLIDATION II	MEDICAL ONCOLOGY	3200	3200	3200	3200	3200	3200	3200	3200
CM0952A-IV-ii-b-4 : Multiagent Chemotherapy + TKIs MAINTENANCE	MEDICAL ONCOLOGY	6410	6410	6410	6410	6410	6410	6410	6410
CM0952A-IV-ii-b-5 : Imatinib	MEDICAL ONCOLOGY	1525	1525	1525	1525	1525	1525	1525	1525
CM0952A-IV-ii-b-6 : Nilotinib	MEDICAL ONCOLOGY	17800	17800	17800	17800	17800	17800	17800	17800
CM0952A-IV-ii-c : Corticosteroids + TKIs	MEDICAL ONCOLOGY	9035	9035	9035	9035	9035	9035	9035	9035
CM0952A-IV-ii-d : Other Regimen	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0952A-IV-iii : Ph(-) AYA (Age 15-39 years)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0952A-IV-iii-a-1 : GRAALL-2003 INDUCTION	MEDICAL ONCOLOGY	15678	15678	15678	15678	15678	15678	15678	15678
CM0952A-IV-iii-a-2 : GRAALL-2003 SALVAGE	MEDICAL ONCOLOGY	28760	28760	28760	28760	28760	28760	28760	28760
CM0952A-IV-iii-a-3 : GRAALL-2003 CONSOLIDATION	MEDICAL ONCOLOGY	30779	30779	30779	30779	30779	30779	30779	30779
CM0952A-IV-iii-a-4 : GRAALL-2003 Late intensification between consolidation blocks 6 and 7 (for patients in complete remission [CR] after the first induction course)	MEDICAL ONCOLOGY	15495	15495	15495	15495	15495	15495	15495	15495
CM0952A-IV-iii-a-5 : GRAALL-2003 Late intensification between consolidation blocks 6 and 7 (for patients in CR after salvage course)	MEDICAL ONCOLOGY	27210	27210	27210	27210	27210	27210	27210	27210
CM0952A-IV-iii-a-6 : GRAALL-2003 Maintenance	MEDICAL ONCOLOGY	56898	56898	56898	56898	56898	56898	56898	56898
CM0952A-IV-iii-b : CNS Therapy-Treatment of patients with initial CNS involvement:	MEDICAL ONCOLOGY	21155	21155	21155	21155	21155	21155	21155	21155
CM0952A-IV-iii-v : CCG-1961	MEDICAL ONCOLOGY	18310	18310	18310	18310	18310	18310	18310	18310
CM0952A-IV-iii-vi : Other Regimen	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0952A-IV-iv : Ph(-) AYA (Age > 40 years)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0952A-IV-iv-a-1 : CALGB 8811 (Larson Regimen) INDUCTION	MEDICAL ONCOLOGY	18038	18038	18038	18038	18038	18038	18038	18038
CM0952A-IV-iv-a-2 : CALGB 8811 (Larson Regimen) CONSOLIDATION	MEDICAL ONCOLOGY	16685	16685	16685	16685	16685	16685	16685	16685
CM0952A-IV-iv-b-1 : Hyper-CVAD with or without Rituximab CYCLE 1,3,5,7	MEDICAL ONCOLOGY	60970	60970	60970	60970	60970	60970	60970	60970
CM0952A-IV-iv-b-2 : Hyper-CVAD with or without Rituximab CYCLE 2,4,6,8	MEDICAL ONCOLOGY	56820	56820	56820	56820	56820	56820	56820	56820
CM0952A-IV-iii-c : Other Regimen	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0953A : All Lymphoma Chemotheraphy	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0953A-I : Hodgkins Lymphoma	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0953A-I-a : ABVD	MEDICAL ONCOLOGY	4480	4480	4480	4480	4480	4480	4480	4480
CM0953A-I-b : Escalated BEACOPP	MEDICAL ONCOLOGY	7119	7119	7119	7119	7119	7119	7119	7119
CM0953A-I-c : ABVD + Rituximab (cyled every 4 weeks)	MEDICAL ONCOLOGY	28480	28480	28480	28480	28480	28480	28480	28480
CM0953A-I-d-i : ABVD + Rituximab (1 cycle - weekly rituximab 4 doses) followed by ABVD	MEDICAL ONCOLOGY	102480	102480	102480	102480	102480	102480	102480	102480
CM0953A-I-d-ii : ABVD	MEDICAL ONCOLOGY	4480	4480	4480	4480	4480	4480	4480	4480
CM0953A-I-e-i : CHOP + Rituximab	MEDICAL ONCOLOGY	26818	26818	26818	26818	26818	26818	26818	26818
CM0953A-I-e-ii : CHOP	MEDICAL ONCOLOGY	2818	2818	2818	2818	2818	2818	2818	2818
CM0953A-I-f-i : CVP +/- Rituximab	MEDICAL ONCOLOGY	25768	25768	25768	25768	25768	25768	25768	25768
CM0953A-I-f-ii : CVP	MEDICAL ONCOLOGY	1768	1768	1768	1768	1768	1768	1768	1768
CM0953A-I-g : Rituximab	MEDICAL ONCOLOGY	25500	25500	25500	25500	25500	25500	25500	25500
CM0953A-I-h : Other Regimen	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0953A-II : Waldenstrom's Macroglobulinemia/ Lymphoplasmacytic Lymphoma	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0953A-II-a : Bortezomib + dexamethasone	MEDICAL ONCOLOGY	68038	68038	68038	68038	68038	68038	68038	68038
CM0953A-II-b : Cyclophosphamide + doxorubicin + vincristine + prednisone + rituximab	MEDICAL ONCOLOGY	26818	26818	26818	26818	26818	26818	26818	26818
CM0953A-II-c : Rituximab	MEDICAL ONCOLOGY	25500	25500	25500	25500	25500	25500	25500	25500
CM0953A-II-d : Rituximab + cyclophosphamide + prednisone	MEDICAL ONCOLOGY	25738	25738	25738	25738	25738	25738	25738	25738
CM0953A-II-e : Rituximab + cyclophosphamide + dexamethasone	MEDICAL ONCOLOGY	25520	25520	25520	25520	25520	25520	25520	25520
CM0953A-II-f-i : Thalidomide with or without rituximab (Weeks 1 and 2)	MEDICAL ONCOLOGY	2540	2540	2540	2540	2540	2540	2540	2540
CM0953A-II-f-ii : Thalidomide with or without rituximab (Weeks 3-50)	MEDICAL ONCOLOGY	6000	6000	6000	6000	6000	6000	6000	6000
CM0953A-II-f-iii : Thalidomide with or without rituximab (Weeks 50-52)	MEDICAL ONCOLOGY	6000	6000	6000	6000	6000	6000	6000	6000
CM0953A-II-f-iv : Thalidomide with or without rituximab Weeks 2-5 and 13-16	MEDICAL ONCOLOGY	24000	24000	24000	24000	24000	24000	24000	24000
CM0953A-II-g-i : Bendamustine with or without rituximab	MEDICAL ONCOLOGY	36500	36500	36500	36500	36500	36500	36500	36500
CM0953A-II-g-ii : Bendamustine - rituximab	MEDICAL ONCOLOGY	12500	12500	12500	12500	12500	12500	12500	12500
CM0953A-II-h-i : Cladribine with or without rituximab	MEDICAL ONCOLOGY	32250	32250	32250	32250	32250	32250	32250	32250
CM0953A-II-h-ii : Cladribine - rituximab	MEDICAL ONCOLOGY	8250	8250	8250	8250	8250	8250	8250	8250
CM0953A-II-i : Bendamustine	MEDICAL ONCOLOGY	12500	12500	12500	12500	12500	12500	12500	12500
CM0953A-II-j : Chlorambucil	MEDICAL ONCOLOGY	1126	1126	1126	1126	1126	1126	1126	1126
CM0953A-II-k : Fludarabine	MEDICAL ONCOLOGY	12030	12030	12030	12030	12030	12030	12030	12030
CM0953A-II-l : Fludarabine + cyclophosphamide + rituximab (FCR)	MEDICAL ONCOLOGY	32398	32398	32398	32398	32398	32398	32398	32398
CM0953A-II-m : Alemtuzumab	MEDICAL ONCOLOGY	2650	2650	2650	2650	2650	2650	2650	2650
CM0953A-II-n : Other Regimen	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0953A-III : NON HODGKINS LYMPHOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0953A-III-i : BURKITT LYMPHOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0953A-III-i-a -1 : CALGB 10002 Cycle 1:	MEDICAL ONCOLOGY	8967	8967	8967	8967	8967	8967	8967	8967
CM0953A-III-i-a-2 : CALGB 10002 Cycles 2 (beginning Day 8), 4, and 6:	MEDICAL ONCOLOGY	66113	66113	66113	66113	66113	66113	66113	66113
CM0953A-III-i-a-3 : CALGB 10002 Cycles 3, 5, and 7:	MEDICAL ONCOLOGY	33108	33108	33108	33108	33108	33108	33108	33108
CM0953A-III-i-a-4 : CALGB 10002 Cycles 4, and 6:	MEDICAL ONCOLOGY	36413	36413	36413	36413	36413	36413	36413	36413
CM0953A-III-i-b : CODOX-M (original or modified) (cyclophosphamide + doxorubicin + vincristine with intrathecal MTX + cytarabine, followed by systemic MTX and cytarabine) with or without Rituximab	MEDICAL ONCOLOGY	46780	46780	46780	46780	46780	46780	46780	46780
CM0953A-III-i-c-1 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 1 & 2)	MEDICAL ONCOLOGY	32972	32972	32972	32972	32972	32972	32972	32972
CM0953A-III-i-c-2 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 3-6)	MEDICAL ONCOLOGY	32572	32572	32572	32572	32572	32572	32572	32572
CM0953A-III-i-d-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3)	MEDICAL ONCOLOGY	59429	59429	59429	59429	59429	59429	59429	59429
CM0953A-III-i-d-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4)	MEDICAL ONCOLOGY	61880	61880	61880	61880	61880	61880	61880	61880
CM0953A-III-i-d-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7)	MEDICAL ONCOLOGY	10969	10969	10969	10969	10969	10969	10969	10969
CM0953A-III-i-d-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8)	MEDICAL ONCOLOGY	12920	12920	12920	12920	12920	12920	12920	12920
CM0953A-III-i-e-1 : CODOX-M alternated with IVAC (CODOX-M) CODOX-M (original or modified) (cyclophosphamide + doxorubicin + vincristine, plus intrathecal MTX + cytarabine, followed by systemic MTX) alternating with IVAC (ifosfamide + cytarabine + etoposide) and intrathecal MTX with or without Rituximab	MEDICAL ONCOLOGY	46780	46780	46780	46780	46780	46780	46780	46780
CM0953A-III-i-e-2 : CODOX-M alternated with IVAC (IVAC) CODOX-M (original or modified) (cyclophosphamide + doxorubicin + vincristine, plus intrathecal MTX + cytarabine, followed by systemic MTX) alternating with IVAC (ifosfamide + cytarabine + etoposide) and intrathecal MTX with or without Rituximab	MEDICAL ONCOLOGY	42847	42847	42847	42847	42847	42847	42847	42847
CM0953A-III-i-f : RICE (rituximab + ifosfamide + carboplatin + etoposide)	MEDICAL ONCOLOGY	32994	32994	32994	32994	32994	32994	32994	32994
CM0953A-III-i-g : RIVAC (rituximab + ifosfamide + cytarabine + etoposide)	MEDICAL ONCOLOGY	43894	43894	43894	43894	43894	43894	43894	43894
CM0953A-III-i-h : RGDP (rituximab + gemcitabine + dexamethasone + cisplatin)	MEDICAL ONCOLOGY	32255	32255	32255	32255	32255	32255	32255	32255
CM0953A-III-i-i : HDAC + Rituximab	MEDICAL ONCOLOGY	27800	27800	27800	27800	27800	27800	27800	27800
CM0953A-III-i-ii : Other Regimen	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0953A-III-ii : NON HODGKIN LYMPHOMA -- ADULT T-CELL LEUKEMIA / LYMPHOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0953A-III-ii-a-1 : Zidovudine + alpha-interferon (induction)	MEDICAL ONCOLOGY	4580	4580	4580	4580	4580	4580	4580	4580
CM0953A-III-ii-a-2 : Zidovudine + alpha-interferon (Maintenance Therapy)	MEDICAL ONCOLOGY	2100	2100	2100	2100	2100	2100	2100	2100
CM0953A-III-ii-b : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP)	MEDICAL ONCOLOGY	2818	2818	2818	2818	2818	2818	2818	2818
CM0953A-III-ii-c : CHOEP	MEDICAL ONCOLOGY	8640	8640	8640	8640	8640	8640	8640	8640
CM0953A-III-ii-d : Dose-adjusted EPOCH(etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin)	MEDICAL ONCOLOGY	6892	6892	6892	6892	6892	6892	6892	6892
CM0953A-III-ii-e : Other Regimen	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0953A-III-iii : DIFFUSE LARGE B CELL LYMPHOMA	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0953A-III-iii-a : CDE (cyclophosphamide + doxorubicin + etoposide) + rituximab	MEDICAL ONCOLOGY	2500	2500	2500	2500	2500	2500	2500	2500
CM0953A-III-iii-b-1 : CODOX-M alternated with IVAC (CODOX-M) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine)	MEDICAL ONCOLOGY	46780	46780	46780	46780	46780	46780	46780	46780
CM0953A-III-iii-b-2 : CODOX-M alternated with IVAC (IVAC) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine)	MEDICAL ONCOLOGY	42847	42847	42847	42847	42847	42847	42847	42847
CM0953A-III-iii-c-1 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 1&2)	MEDICAL ONCOLOGY	32972	32972	32972	32972	32972	32972	32972	32972
CM0953A-III-iii-c-2 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 3-6)	MEDICAL ONCOLOGY	32572	32572	32572	32572	32572	32572	32572	32572
CM0953A-III-iii-d-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3)	MEDICAL ONCOLOGY	59429	59429	59429	59429	59429	59429	59429	59429
CM0953A-III-iii-d-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4)	MEDICAL ONCOLOGY	61880	61880	61880	61880	61880	61880	61880	61880
CM0953A-III-iii-d-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7)	MEDICAL ONCOLOGY	10969	10969	10969	10969	10969	10969	10969	10969
CM0953A-III-iii-d-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8)	MEDICAL ONCOLOGY	12920	12920	12920	12920	12920	12920	12920	12920
CM0953A-III-iii-e-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) Rituximab	MEDICAL ONCOLOGY	26818	26818	26818	26818	26818	26818	26818	26818
CM0953A-III-iii-e-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP)	MEDICAL ONCOLOGY	2818	2818	2818	2818	2818	2818	2818	2818
CM0953A-III-iii-f : Other Regimen	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0953A-III-iv : AIDS-Related B-Cell Lymphomas	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0953A-III-iv-a : CDE (cyclophosphamide + doxorubicin + etoposide) + rituximab	MEDICAL ONCOLOGY	2500	2500	2500	2500	2500	2500	2500	2500
CM0953A-III-iv-b-1 : CODOX-M alternated with IVAC (CODOX-M) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine)	MEDICAL ONCOLOGY	46780	46780	46780	46780	46780	46780	46780	46780
CM0953A-III-iv-b-2 : CODOX-M alternated with IVAC (IVAC) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine)	MEDICAL ONCOLOGY	42847	42847	42847	42847	42847	42847	42847	42847
CM0953A-III-iv-c-1 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 1&2)	MEDICAL ONCOLOGY	32972	32972	32972	32972	32972	32972	32972	32972
CM0953A-III-iv-c-2 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 3-6)	MEDICAL ONCOLOGY	32572	32572	32572	32572	32572	32572	32572	32572
CM0953A-III-iv-d-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3)	MEDICAL ONCOLOGY	59429	59429	59429	59429	59429	59429	59429	59429
CM0953A-III-iv-d-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4)	MEDICAL ONCOLOGY	61880	61880	61880	61880	61880	61880	61880	61880
CM0953A-III-iv-d-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7)	MEDICAL ONCOLOGY	10969	10969	10969	10969	10969	10969	10969	10969
CM0953A-III-iv-d-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8)	MEDICAL ONCOLOGY	12920	12920	12920	12920	12920	12920	12920	12920
CM0953A-III-iv-e-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) with or without Rituximab	MEDICAL ONCOLOGY	26818	26818	26818	26818	26818	26818	26818	26818
CM0953A-III-iv-e-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP)	MEDICAL ONCOLOGY	2818	2818	2818	2818	2818	2818	2818	2818
CM0953A-III-iv-f : Other Regimen	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0953A-III-v : Primary Cutaneous Marginal Zone or Follicle Center Lymphoma	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0953A-III-v-a-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) with or without Rituximab	MEDICAL ONCOLOGY	26818	26818	26818	26818	26818	26818	26818	26818
CM0953A-III-v-a-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP)	MEDICAL ONCOLOGY	2818	2818	2818	2818	2818	2818	2818	2818
CM0953A-III-v-b : Rituximab	MEDICAL ONCOLOGY	25500	25500	25500	25500	25500	25500	25500	25500
CM0953A-III-v-c : Other Regimen	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0953A-III-vi : Follicular Lymphoma (Grade 1-2)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0953A-III-vi-a-1 : Bendamustine with or without rituximab	MEDICAL ONCOLOGY	36500	36500	36500	36500	36500	36500	36500	36500
CM0953A-III-vi-a-2 : Bendamustine (-) rituximab	MEDICAL ONCOLOGY	12500	12500	12500	12500	12500	12500	12500	12500
CM0953A-III-vi-b-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) with or without Rituximab	MEDICAL ONCOLOGY	26818	26818	26818	26818	26818	26818	26818	26818
CM0953A-III-vi-b-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP)	MEDICAL ONCOLOGY	2818	2818	2818	2818	2818	2818	2818	2818
CM0953A-III-vi-c : Cyclophosphamide + Vincristine + Prednisone + Rituximab (RCVP)	MEDICAL ONCOLOGY	25768	25768	25768	25768	25768	25768	25768	25768
CM0953A-III-vi-d : Rituximab	MEDICAL ONCOLOGY	25500	25500	25500	25500	25500	25500	25500	25500
CM0953A-III-vi-e : Lenalidomide + Rituximab	MEDICAL ONCOLOGY	4940	4940	4940	4940	4940	4940	4940	4940
CM0953A-III-vi-f : Other Regimen	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0953A-III-vii : Extranodal NK/T-Cell Lymphoma	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0953A-III-vii-a : SMILE	MEDICAL ONCOLOGY	27483	27483	27483	27483	27483	27483	27483	27483
CM0953A-III-vii-b : DeVIC +RT	MEDICAL ONCOLOGY	9163	9163	9163	9163	9163	9163	9163	9163
CM0953A-III-vii-c : VIPID	MEDICAL ONCOLOGY	6619	6619	6619	6619	6619	6619	6619	6619
CM0953A-III-vii-d : Other Regimen	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0954 : Myelodysplastic Syndromes Treatment Regimens	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0954-i : Symptomatic Anemia With del(5q) with or without Other Cytogenetic Abnormalities	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0954-i-a : Lenalidomide	MEDICAL ONCOLOGY	2575	2575	2575	2575	2575	2575	2575	2575
CM0954-ii : Symptomatic Anemia Without del(5q) and Serum Erythropoietin =500mU/mL	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0954-ii-a-1 : rHu-Epo with or without G-CSF	MEDICAL ONCOLOGY	26080	26080	26080	26080	26080	26080	26080	26080
CM0954-ii-a-2 : rHu-Epo (-) G-CSF	MEDICAL ONCOLOGY	25750	25750	25750	25750	25750	25750	25750	25750
CM0954-ii-b-1 : Darbepoetin alfa with or without G-CSF	MEDICAL ONCOLOGY	9330	9330	9330	9330	9330	9330	9330	9330
CM0954-ii-b-2 : Darbepoetin alfa (-) G-CSF	MEDICAL ONCOLOGY	9000	9000	9000	9000	9000	9000	9000	9000
CM0954-iii : Symptomatic Anemia Without del(5q), Serum Erythropoietin >500mU/mL, Unlikely to Respond to IST	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0954-iii-a-1 : Decitabine (15mg/m2)	MEDICAL ONCOLOGY	15500	15500	15500	15500	15500	15500	15500	15500
CM0954-iii-a-2 : Decitabine (20mg/m2)	MEDICAL ONCOLOGY	16500	16500	16500	16500	16500	16500	16500	16500
CM0954-iii-b : Lenalidomide	MEDICAL ONCOLOGY	2575	2575	2575	2575	2575	2575	2575	2575
CM0955 : Multiple Myeloma	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0955-a : Lenalidomide (28 days) + Dexamethasone	MEDICAL ONCOLOGY	6817	6817	6817	6817	6817	6817	6817	6817
CM0955-b : Lenalidomide (21 days) + Dexamethasone	MEDICAL ONCOLOGY	5004	5004	5004	5004	5004	5004	5004	5004
CM0955-c : Lenalidomide	MEDICAL ONCOLOGY	2575	2575	2575	2575	2575	2575	2575	2575
CM0955-d : Bendamustine + Lenalidomide + Dexamethasone	MEDICAL ONCOLOGY	13639	13639	13639	13639	13639	13639	13639	13639
CM0955-e : Bendamustine	MEDICAL ONCOLOGY	22000	22000	22000	22000	22000	22000	22000	22000
CM0955-f : Cyclophosphamide + Lenalidomide + Dexamethasone	MEDICAL ONCOLOGY	5136	5136	5136	5136	5136	5136	5136	5136
CM0955-g : Dexamethasone + Cyclophosphamide + Etoposide + Cisplatin (DCEP)	MEDICAL ONCOLOGY	5764	5764	5764	5764	5764	5764	5764	5764
CM0955-h : Dexamethasone + Thalidomide + Cisplatin + Doxorubicin + Cyclophosphamide + Etoposide (DT-PACE)	MEDICAL ONCOLOGY	7724	7724	7724	7724	7724	7724	7724	7724
CM0955-i : High-dose Cyclophosphamide	MEDICAL ONCOLOGY	5140	5140	5140	5140	5140	5140	5140	5140
CM0955-j : VAD / VAMP	MEDICAL ONCOLOGY	6104	6104	6104	6104	6104	6104	6104	6104
CM0955-k : Melphalan	MEDICAL ONCOLOGY	3900	3900	3900	3900	3900	3900	3900	3900
CM0955-l : Melphalan + Prednisolone	MEDICAL ONCOLOGY	1137	1137	1137	1137	1137	1137	1137	1137
CM0955-m : Thalidomide + Dexamethasone	MEDICAL ONCOLOGY	2376	2376	2376	2376	2376	2376	2376	2376
CM0955-n : Melphalan / Prednisolone/Thalidomide(MPT)	MEDICAL ONCOLOGY	2257	2257	2257	2257	2257	2257	2257	2257
CM0956 : ALL LYMPHOMA SALVAGE CHEMO (Package 953 to be utilised)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0957 : CHILDHOOD B CELL LYMPHOMA VARIABLE REGIMEN (Package 953 to be utilised)	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0100-N : BREAST CANCER - TAMOXIFEN	MEDICAL ONCOLOGY	100	100	100	100	100	100	100	100
CM0100-O : BREAST CANCER - AROMATASE INHIBITORS	MEDICAL ONCOLOGY	1000	1000	1000	1000	1000	1000	1000	1000
CM0100-P : BREAST CANCER - Zoledronic Acid for skeletal metastasis	MEDICAL ONCOLOGY	2700	2700	2700	2700	2700	2700	2700	2700
CM0124-c : PROSTATE CANCER - Zoledronic Acid for skeletal metastasis	MEDICAL ONCOLOGY	2700	2700	2700	2700	2700	2700	2700	2700
CM0955-O : Multiple Myeloma - Zoledronic Acid	MEDICAL ONCOLOGY	2700	2700	2700	2700	2700	2700	2700	2700
CM0100-a-III : BREAST CANCER - Paclitaxel (Preceeded by Dose Dense AC - 4 cycles) ; (Day 1: Paclitaxel 175mg/m2) Repeat cycle - every 21 days for 4 cycles	MEDICAL ONCOLOGY	7000	7000	7000	7000	7000	7000	7000	7000
CM0100-a-IV : BREAST CANCER - Paclitaxel (Preceeded by Dose Dense AC - 4 cycles) ; (Day 1: Paclitaxel 80mg/m2) Repeat cycle - weekly for 12 cycles	MEDICAL ONCOLOGY	3500	3500	3500	3500	3500	3500	3500	3500
CM0101-a-IV : BLADDER CANCER - Radiosensitizing - Cisplatinc + 5-FU ; Days 1, 2, 3, 15, 16, and 17: IV hydration at a rate of 500mL/hour; followed by 5-FU 400mg/m2 IV push; followed by cisplatin 15mg/m2 IV over 1 hour as induction and consolidation therapy	MEDICAL ONCOLOGY	9800	9800	9800	9800	9800	9800	9800	9800
CM0101-a-V : BLADDER CANCER -Radiosensitizing - Cisplatin + paclitaxel ; Days 1, 8, and 15: Paclitaxel 50mg/m2 ; Day 1-3, 8-10, 15-17: Cisplatin 15mg/m2; followed by twice-daily radiotherapy for 8 days	MEDICAL ONCOLOGY	18400	18400	18400	18400	18400	18400	18400	18400
CM0101-a-VI : BLADDER CANCER -Radiosensitizing - 5-FU + mitomycin32 ; Day 1 of radiotherapy: Mitomycin 12mg/m2 IV bolus, plus ; Week 1 (fractions 1-5) and Week 4 (fractions 16-20) of radiotherapy: 5-FU 500mg/m2 continuous IV infusion (10 days total)	MEDICAL ONCOLOGY	15100	15100	15100	15100	15100	15100	15100	15100
CM0101-c : BLADDER CANCER - Concurrent Cisplatin; Cisplatin 40mg/m2 IV once weekly for up to 5 cycles	MEDICAL ONCOLOGY	1800	1800	1800	1800	1800	1800	1800	1800
CM0103 : OESOPHAGEAL CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0103-v: ESOPHAGEAL CANCER - Concurrent Cisplatin; Cisplatin 40mg/m2 IV once weekly for up to 5 cycles	MEDICAL ONCOLOGY	1800	1800	1800	1800	1800	1800	1800	1800
CM0105 : COLORECTAL CANCER	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0106 : OSTEOSARCOMA/ BONE TUMORS	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0106-vi : Other bone tumors - Mesenchymal Chordosarcoma VIDE (vincristine + ifosfamide + doxorubicin + etoposide) ; Day 1: Vincristine 1.4mg/m2 (max 2mg), ; Days 1-3: Doxorubicin 20mg/m2 IV + ifosfamide 3mg/m2 IV + mesna 3g/m2 + etoposide 150mg/m2 IV. ; Repeat cycle every 3 weeks for up to 6 cycles.	MEDICAL ONCOLOGY	9200	9200	9200	9200	9200	9200	9200	9200
CM0110 : Neuroblastoma ALL STAGES	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM0114-i-b-1 : EWINGS SARCOMA - Induction Treatment - VAC/IE - VAC ; Day 1: Vincristine 2mg/m2 (max 2mg) IV, doxorubicin 75mg/m2 IV bolus, cyclophosphamide 1,200mg/m2 IV, mesna. ; Dactinomycin 1.25mg/m2 IV can be substituted for doxorubicin when a total doxorubicin dose of 375mg/m2 is reached.	MEDICAL ONCOLOGY	4600	4600	4600	4600	4600	4600	4600	4600
CM0114-i-b-2 : EWINGS SARCOMA - Induction Treatment - VAC/IE - IE ; IE cycles ; Days 1-5: Ifosfamide 1,800mg/m2 IV + mesna + etoposide 100mg/m2 IV. ; Repeat each cycle every 3 weeks for 17 cycles.	MEDICAL ONCOLOGY	6000	6000	6000	6000	6000	6000	6000	6000
CM0114-i-e : EWINGS SARCOMA - Induction Treatment - VACA ; Day 1: Vincristine 1.5mg/m2 IV + cyclophosphamide 1,200mg/m2 IV + mesna ; Days 1, 3, and 5: Dactinomycin 0.5mg/m2 IV ; Days 2 and 4: Doxorubicin 30mg/m2 IV. ; Repeat cycle every 21 days for 10 cycles.	MEDICAL ONCOLOGY	4600	4600	4600	4600	4600	4600	4600	4600
CM0117-e : VULVAL CANCER - Cisplatin + 5FU ; Days 1 and 29: Cisplatin 50mg/m2 IV ; Days 2-5, and 30-33: 5-FU 1,000mg/m2 IV	MEDICAL ONCOLOGY	11100	11100	11100	11100	11100	11100	11100	11100
CM0128-ii-c-1 : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - Concurrent Temozolomide (with RT) - followed by adjuvant temozolomide ; Daily oral temozolomide (75mg/m2/day, 7 days per week from the first to the last day of radiotherapy)	MEDICAL ONCOLOGY	7200	7200	7200	7200	7200	7200	7200	7200
CM0128-ii-c-2 : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - adjuvant temozolomide - preceeded by Concurrent Temozolomide (with RT) ; Temozolomide 150-200mg/m2/day for 5 days. ; Repeat cycle every 28 days for 6 cycles	MEDICAL ONCOLOGY	2100	2100	2100	2100	2100	2100	2100	2100
CM0130 I a : RENAL CELL CARCINOMARENAL CELL CARCINOMA - First-line Therapy for Patients with Predominantly Clear Cell Histology - Pazopanib ; Pazopanib 800mg orally once daily	MEDICAL ONCOLOGY	19250	19250	19250	19250	19250	19250	19250	19250
CM0130 I b : RENAL CELL CARCINOMARENAL CELL CARCINOMA - First-line Therapy for Patients with Predominantly Clear Cell Histology - Sunitinib ; Sunitinib 50mg orally daily for 4 weeks, followed by 2 weeks off.	MEDICAL ONCOLOGY	29250	29250	29250	29250	29250	29250	29250	29250
CM0130 I c : RENAL CELL CARCINOMARENAL CELL CARCINOMA - First-line Therapy for Patients with Predominantly Clear Cell Histology - Bevacizumab + IFN-alpha ; Bevacizumab 10mg/kg IV every 2 weeks + IFN-alpha.	MEDICAL ONCOLOGY	66750	66750	66750	66750	66750	66750	66750	66750
CM0130 I d : RENAL CELL CARCINOMARENAL CELL CARCINOMA - First-line Therapy for Patients with Predominantly Clear Cell Histology - Sorafenib ; Sorafenib 400mg orally twice daily	MEDICAL ONCOLOGY	3650	3650	3650	3650	3650	3650	3650	3650
CM0130 II a : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Everolimus ; Everolimus 10mg orally once daily	MEDICAL ONCOLOGY	37250	37250	37250	37250	37250	37250	37250	37250
CM0130 II b : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Pazopanib ; Pazopanib 800mg orally once daily	MEDICAL ONCOLOGY	19250	19250	19250	19250	19250	19250	19250	19250
CM0130 II c : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Sorafenib ; Sorafenib 400mg orally twice daily	MEDICAL ONCOLOGY	3650	3650	3650	3650	3650	3650	3650	3650
CM0130 II d : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Sunitinib ; Sunitinib 50mg orally daily for 4 weeks, followed by 2 weeks off.	MEDICAL ONCOLOGY	29250	29250	29250	29250	29250	29250	29250	29250
CM0130 II e : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Bevacizumab ; Bevacizumab 10mg/kg IV every 2 weeks.	MEDICAL ONCOLOGY	66250	66250	66250	66250	66250	66250	66250	66250
CM0130 III a : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Sunitinib ; Sunitinib 50mg orally daily for 4 weeks, followed by 2 weeks off.	MEDICAL ONCOLOGY	29250	29250	29250	29250	29250	29250	29250	29250
CM0130 III b : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Bevacizumab ; Bevacizumab 10mg/kg IV every 2 weeks.	MEDICAL ONCOLOGY	66250	66250	66250	66250	66250	66250	66250	66250
CM0130 III c : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Everolimus ; Everolimus 10mg orally once daily	MEDICAL ONCOLOGY	37250	37250	37250	37250	37250	37250	37250	37250
CM0130 III d : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Erlotinib ; Erlotinib 150mg orally once daily	MEDICAL ONCOLOGY	3400	3400	3400	3400	3400	3400	3400	3400
CM0130 III e : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Pazopanib ; Pazopanib 800mg orally once daily	MEDICAL ONCOLOGY	19250	19250	19250	19250	19250	19250	19250	19250
CM0130 III f : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Sorafenib ; Sorafenib 400mg orally twice daily	MEDICAL ONCOLOGY	3650	3650	3650	3650	3650	3650	3650	3650
CM0130 IV: RENAL CELL CARCINOMARENAL CELL CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents)	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0131-i-g : UNKNOWN PRIMARY - Adenocarcinoma - mFOLFOX ; Day 1: Oxaliplatin 85mg/m2 IV over 2 hours + leucovorin 400mg/m2 IV over 2 hours + 5-FU 400mg/m2 IV bolus then ; Days 1 and 2: 5-FU 1200mg/m2 (total 2400mg/m2 over 46-48 hours) IV continuous infusion. ; Repeat cycle every 2 weeks for 24 cycles	MEDICAL ONCOLOGY	8000	8000	8000	8000	8000	8000	8000	8000
CM0131-i-h : UNKNOWN PRIMARY - Adenocarcinoma - CapeOX ; Day 1: Oxaliplatin 130mg/m2 IV over 2 hours ; Day 1-14: Capecitabine 850-1000mg/m2 orally twice daily. ; Repeat cycle every 3 weeks for 16 cycles.	MEDICAL ONCOLOGY	6500	6500	6500	6500	6500	6500	6500	6500
CM0131-i-i : UNKNOWN PRIMARY - Adenocarcinoma - Irinotecan + carboplatin ; Day 1: Carboplatin AUC 5mg per min/mL IV ; Days 1, 8, and 15: Irinotecan 60mg/m2 IV. ; Repeat cycle every 4 weeks for up to 6 cycles	MEDICAL ONCOLOGY	7700	7700	7700	7700	7700	7700	7700	7700
CM0131-ii-c : UNKNOWN PRIMARY - Squamous cell carcinoma -Paclitaxel + carboplatin ; Day 1: Carboplatin AUC 6mg per min/mL IV over 30 minutes + paclitaxel 200mg/m2 IV over 3 hours. ; Repeat cycle every 3 weeks for 8 cycles in responding patients and for 6 cycles maximum in patients with stable disease	MEDICAL ONCOLOGY	7200	7200	7200	7200	7200	7200	7200	7200
CM0131-ii-d : UNKNOWN PRIMARY - Squamous cell carcinoma -Cisplatin + gemcitabine ; Day 1: Cisplatin 100mg/m2 IV ; Day 1 and 8: Gemcitabine 1250mg/m2 IV. ; Repeat every 3 weeks for 4 cycles.	MEDICAL ONCOLOGY	5250	5250	5250	5250	5250	5250	5250	5250
CM0131-ii-e : UNKNOWN PRIMARY - Squamous cell carcinoma -mFOLFOX ; Day 1: Oxaliplatin 85mg/m2 IV over 2 hours + leucovorin 400mg/m2 IV over 2 hours + 5-FU 400mg/m2 IV bolus then ; Days 1 and 2: 5-FU 1200mg/m2 (total 2400mg/m2 over 46-48 hours) IV continuous infusion. ; Repeat cycle every 2 weeks for 24 cycles.	MEDICAL ONCOLOGY	8000	8000	8000	8000	8000	8000	8000	8000
CM0131-ii-f : UNKNOWN PRIMARY - Squamous cell carcinoma -Paclitaxel + cisplatin ; Day 1: Paclitaxel 175mg/m2 IV + cisplatin 60mg/m2 IV. ; Repeat cycle every 3 weeks.	MEDICAL ONCOLOGY	6450	6450	6450	6450	6450	6450	6450	6450
CM0131-ii-g : UNKNOWN PRIMARY - Squamous cell carcinoma -Docetaxel + carboplatin ; Day 1: Docetaxel 75mg/m2 IV over 30 minutes + carboplatin AUC 5mg per min/mL IV over 30 minutes. ; Repeat cycle every 3 weeks for 8 cycles	MEDICAL ONCOLOGY	8700	8700	8700	8700	8700	8700	8700	8700
CM0131-ii-h : UNKNOWN PRIMARY - Squamous cell carcinoma -Docetaxel + cisplatin ; Day 1: Docetaxel 60mg/m2 IV + cisplatin 80mg/m2 IV. ; Repeat cycle every 3 weeks for 2 cycles and an additional 4 cycles until disease progression is demonstrated	MEDICAL ONCOLOGY	5040	5040	5040	5040	5040	5040	5040	5040
CM0131-ii-i : UNKNOWN PRIMARY - Squamous cell carcinoma -Docetaxel + cisplatin ; Day 1: Docetaxel 75mg/m2 IV + cisplatin 75mg/m2 IV. ; Repeat cycle every 3 weeks for up to 6 cycles.	MEDICAL ONCOLOGY	3820	3820	3820	3820	3820	3820	3820	3820
CM0131-ii-j : UNKNOWN PRIMARY - Squamous cell carcinoma -Cisplatin + fluorouracil ; Days 1-5: Cisplatin 20mg/m2 IV ; Days 1-5: Fluorouracil 700mg/m2/day IV via continuous infusion over 24 hours. ; Repeat cycle every 4 weeks for 3 cycles.	MEDICAL ONCOLOGY	7050	7050	7050	7050	7050	7050	7050	7050
CM0952A-I-iii-j : Chronic Myeloid Leukemia (CML) - Other Regimen	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM0952A-II-z : Acute Myeloid Leukemia (AML) - Other Regimen	MEDICAL ONCOLOGY	10000	10000	10000	10000	10000	10000	10000	10000
CM1419 : Acute lymphoblastic leukemia: Supportive care/ rehabilitation	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM1420 : Acute myeloid leukemia: Supportive care/ rehabilitation	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM1421 : Hodgkin Lymphoma (Favorable group): Supportive care/ rehabilitation	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM1422 : Hodgkin Lymphoma (unfavorable group): Supportive care/ rehabilitation	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM1423 : Non-Hodgkin Lymphoma: Supportive care/ rehabilitation	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM1424 : Retinoblastoma (Intraocular): supportive care/ rehabilitation	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM1425 : Retinoblastoma (extraocular): supportive care/ rehabilitation	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM1426 : Brain tumors: supportive care/ rehabilitation	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM1427 : Histiocytosis: supportive care/ rehabilitation	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM1428 : Bone tumors/soft tissue sarcomas : supportive care/ rehabilitation	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM1429 : Chronic Myeloid Leukemia : supportive care/ rehabilitation	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM1430 : Terminally IllPalliative And Supportive Therapy - Per month	MEDICAL ONCOLOGY	0	0	0	0	0	0	0	0
CM1419 A : Acute lymphoblastic leukemia: Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN	MEDICAL ONCOLOGY	20000	20000	20000	20000	20000	20000	20000	20000
CM1420 A : Acute myeloid leukemia: Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage	MEDICAL ONCOLOGY	30000	30000	30000	30000	30000	30000	30000	30000
CM1421 A : Hodgkin Lymphoma (Favorable group): Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN	MEDICAL ONCOLOGY	15000	15000	15000	15000	15000	15000	15000	15000
CM1422 A : Hodgkin Lymphoma (unfavorable group): Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN	MEDICAL ONCOLOGY	25000	25000	25000	25000	25000	25000	25000	25000
CM1423 A : Non-Hodgkin Lymphoma: Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN	MEDICAL ONCOLOGY	50000	50000	50000	50000	50000	50000	50000	50000
CM1429 A : Chronic Myeloid Leukemia : supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN	MEDICAL ONCOLOGY	20000	20000	20000	20000	20000	20000	20000	20000
CM1430 A : Terminally Ill - Pain management (Opioid therapy / Neural Blocks / epidural or Intrathecal infusions / Antero-lateral spinal cordotomy (tractotomy) by RFA) / TPN - Per month	MEDICAL ONCOLOGY	3000	3000	3000	3000	3000	3000	3000	3000

Package Rates

Say hello to us , Toll-Free

Write to us

Reach us At